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ABSTRACT
Amyotrophic lateral sclerosis (ALS) is a complex, progressive and fatal
motor neuron disease. There are currently no effective treatments for ALS.
P2X7 receptor is a ligand-gated cation channel, which is activated by
extracellular adenosine 5’-triphosphate (ATP) and present in the periphery
and in the central nervous system (CNS). Among different factors
contributing to the progression of ALS, the involvement of ATP-P2X7
signalling axis plays a role in this disease through the activation of microglia
and astrocytes to promote death of motor neurons. Whilst the ectoATPase
CD39, which hydrolyses extracellular ATP, is down-regulated in ALS
leading to the potential accumulation of extracellular ATP and subsequent
activation of the P2X7 receptor channel to promote disease. In order to
understand the roles of the ATP-P2X7 signalling axis in ALS, cellular
models that closely resemble ALS-associated models would be beneficial to
establish. Furthermore, the use of CNS-penetrant P2X7 antagonists might
further establish the role of the P2X7 receptor in ALS progression in vivo.
Thus, this study aims to investigate P2X7 receptor and CD39 on murine
EOC13 microglia to determine if it may serve as a suitable in vitro model of
these molecules on microglia in ALS (Chapter 2). Moreover, this study aims
to determine if CNS-penetrant P2X7 antagonists JNJ-47965567 ameliorates
disease progression in SOD1 ALS mice (Chapter 3).

x

In Chapter 2, P2X7 and CD39 expression was determined by qPCR and flow
cytometry. P2X7 activity was measured by a fixed-time ethidium+ uptake
assay. CD39 activity was measured using the molybdite assay. qPCR and
flow cytometry confirmed the presence of high amount of P2X7 receptor and
a low amount of CD39 on EOC13 microglia. Pre-incubation of EOC13
microglia with the CNS penetrant P2X7 antagonist, JNJ-47965567, impaired
ATP-induced cation uptake confirming the presence of functional P2X7 on
these cells. This study also revealed negligible ectoATPase activity on
EOC13 cells. These results demonstrate that murine EOC13 microglia
express a relatively high level of P2X7 but low level of CD39 when
compared to murine spleen cells. This pattern reflects that of ALS-associated
microglia, indicating EOC13 microglia may serve as a potential model to
study the ATP-P2X7 signalling axis in microglial events relating to ALS.
In Chapter 3, to investigate the therapeutic efficacy of CNS-penetrant P2X7
antagonists JNJ-47965567, SOD1G93A transgenic mice were injected
intraperitoneally with JNJ-47965567 or vehicle solution from d 101-103
(i.e., disease onset) until end-stage. SOD1G93A mice were monitored for the
progression of ALS by measuring body weight, clinical score, motor
coordination and survival. In the current study, the CNS-penetrant P2X7
receptor antagonist JNJ-47965567 did not alter disease progression in ALS
SOD1G93A mice. This result was the same in either male or female SOD1G93A

xi

mice, or when combined into treatment groups of both genders. Thus, this
study suggests that the blockade of periphery and CNS P2X7 receptors is
insufficient to ameliorate ALS progression in SOD1G93A mice.

xii

Chapter 1
Introduction
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1.1 Amyotrophic lateral sclerosis
1.1.1 Introduction
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's or Charcot
disease, was first described by Jean-Martin Charcot in 1874 (Rowland 2001).
ALS is a progressive motor neuron disease in which motor neurons die in
the motor cortex, brain stem, and spinal cord (Boillee et al. 2006)
(Figure 1.1). Two forms of ALS have been identified; sporadic ALS (sALS)
and familial ALS (fALS) (Harikrishnareddy et al. 2015). Almost 90% of
ALS patients suffer from the sporadic form and only 10% patients suffer
from the familial form (Harikrishnareddy et al. 2015). Two to three people
suffer from ALS per 100,000 (Al-Chalabi and Hardiman 2013). The
incidence rate of ALS is higher in males than in females, possessing a risk
ratio of 1:350 and 1:400 for males and females respectively (Al-Chalabi and
Hardiman 2013). ALS is a fatal disorder in which most patients do not
survive more than 3 to 5 years following diagnosis (Wijesekera and Leigh
2009). Despite decades of research, riluzole (Bensimon et al. 1994) and
edaravone (Abe et al. 2014) remain the only drugs approved by Food and
Drug Administration, however both have limited efficacy on ALS patients.
Thus, there is an urgent need of more effective drugs for the treatment of this
incurable disorder.
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Motor
cortex
Brainstem

Spinal
cord

Skeletal
muscle

A. Normal

B. ALS

Figure 1.1 Affected areas in the central nervous system (CNS) in amyotrophic lateral
sclerosis (ALS). (A) In normal conditions, skeletal muscles receive signals from the
brain. (B) In ALS, the death of motor neurons in the motor cortex, brainstem and spinal
cord prevents signal transfer to the skeletal muscles resulting in muscle weakness and
paralysis.

The hallmark of ALS is the presence of lower and upper motor neuron signs
and symptoms. ALS can present with four different types of onset; limbic
onset, bulbar onset, primary lateral sclerosis and progressive muscular
atrophy (Kiernan et al. 2011, Al-Chalabi and Hardiman 2013). In limbic
onset, voluntary muscles of both upper and lower limbs are affected causing
muscles weakness, fasciculation, spasticity, wasting and tendon reflexes.
Bulbar onset is mainly characterised by difficulty in speaking, breathing and
swallowing. Primary lateral sclerosis and progressive muscular atrophy
involve dysfunction in the upper and lower motor neurons, respectively.
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1.1.2 Disease Mechanisms in ALS
The disease mechanism in ALS is a complex process involving multiple
factors. Despite numerous studies, disease pathogenesis in ALS is still not
clear. Gene mutation, epigenetic regulation and environmental exposure
have been associated with ALS causes (Paez-Colasante et al. 2015). Gene
mutation is considered one of the major reasons for the occurrence of fALS.
Mutation in genes such as C9orf72, SOD1, TARDBP (TDP-43) and FUS
occur frequently, however mutation in 40 other genes have also been
associated with ALS (Al-Chalabi et al. 2017). Among all genetic mutations,
mutation in C9orf72 is the most common, accounting for 40-50% of total
familial cases. Mutation in SOD1 accounts for 20% of fALS, TARDBP and
FUS account for 1-5% of fALS, and ANG accounts for <1% of fALS
(Robberecht and Philips 2013). Although genetic mutation is closely
associated with fALS, studies conducted in monozygotic twins discovered
an association of epigenetic regulation such as deoxyribonucleic acid (DNA)
methylation, histone remodeling, ribonucleic acid (RNA) editing and
non-coding RNAs in ALS patients with no family history of ALS
(Paez-Colasante et al. 2015). Along with genetic contribution, different
environmental factors are also known to contribute in the onset of ALS
(Al-Chalabi and Hardiman 2013).
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1.1.2.1 Mutations in the gene coding Cu-Zn superoxide dismutase-1
(SOD1)
The SOD1 gene was the first gene identified as the genetic cause of ALS
(Rosen et al. 1993). The SOD1 gene is located on chromosome 21 in humans.
Five exons in this chromosome encode the Cu-Zn superoxide dismutase-1
(SOD1) subunit, a protein consisting of 153 amino acids, which when bound
with copper and zinc forms a SOD1 homodimer (Turner and Talbot 2008).
The dimeric form of SOD1 acts as an antioxidant, metabolising the toxic
radical superoxide to molecular oxygen and hydrogen peroxide (Rosen et al.
1993, Kaur et al. 2016). Mutations in the SOD1 gene results in
conformational instability of the protein, which leads to the formation of
large intracellular protein aggregates that contribute to motor neuron death
(Bruijn et al. 1998) (Figure 1.2).
SOD1
dimer
Normal

Unstable
monomer

Protein
aggregate

Function

Scavenges cytotoxic
radicals

SOD1 gene
Motor neuron death
Mutant
(eg: G93A)

Figure 1.2 Cu-Zn superoxide dismutase-1 (SOD1) in amyotrophic lateral sclerosis
(ALS). In normal conditions, the SOD1 gene encodes Cu-Zn superoxide dismutase-1
(SOD1) subunit, which when bound with copper and zinc forms a SOD1 homodimer. The
dimeric form of SOD1 acts as an antioxidant metabolising cytotoxic radicals. Mutations
in the SOD1 gene results in unstable monomers resulting in large intracellular protein
aggregates, which lead to motor neuron death causing ALS. Figure adapted from
Kaur et al. 2016.
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Some 130 mutations (such as G93A, G37R, and G85R) occur in the SOD1
gene (AL-Chalabi et al. 2017), among which the G93A missense mutation
is the most studied. The G93A mutation results in the substitution of the
glycine residue at position 93 by an alanine residue in the SOD1 subunit
(Kaur et al. 2016). Following the discovery of this mutation in ALS, a
number of rodent models of ALS overexpressing human mutant SOD1
(mSOD1) have been developed that resembles human ALS (Turner and
Talbot 2008). However, the deletion of SOD1 gene failed to develop
ALS-like phenotype in mice (Reaume et al. 1996), which suggest that mutant
SOD1 cause toxicity by gain of other pathogenic mechanisms rather than
loss of enzymatic function of SOD1. The transgenic mice and rat models
have been important tools to further understand early and late
pathophysiological mechanisms associated with mSOD1 and to evaluate
potential therapeutic strategies in ALS (McGoldrick et al. 2013). This
chapter will now discuss insights into ALS pathogenesis obtained from
studies of mSOD1 transgenic mice.
1.1.2.2 Cell and non-cell autonomous mechanisms
Study of the mSOD1 mouse model reveals a number of cell and non-cell
autonomous mechanisms that are involved in the pathophysiology of ALS.
Cell autonomous mechanisms include changes within motor neurons such as
axonal transport defects, mitochondrial dysfunction, increased endoplasmic
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reticulum stress, glutamate toxicity and caspase activation, abnormal RNA
metabolism and impaired proteostasis (Soo et al. 2015, Mathis et al. 2017).
Non-cell autonomous mechanisms include neuroinflammation mediated by
microglia and astrocytes (Hooten et al. 2015). Overall, both cell and non-cell
autonomous mechanisms contribute to motor neuron death in ALS. Since
chapter two aims to study various aspects of microglia in ALS, the latter
sections in this chapter will be focused on microglia-mediated
neuroinflammation in ALS.
Despite the above and other knowledge in disease mechanisms leading to
ALS, the primary factors that trigger ALS remain unknown. Findings from
studies in mSOD1 mice suggest that mSOD1 in motor neurons initiate toxic
actions, which in combination with non-neuronal cells also possessing
mSOD1, accelerates motor neuron death and disease progression. Initially,
two studies failed to demonstrate ALS in transgenic mice such as SOD1G37R,
SOD1G93A, SOD1G85R specifically expressing mSOD1 in neurons
(Pramatarova et al. 2001, Lino et al. 2002). In contrast, in a third study,
SOD1G93A transgenic mice overexpressing mSOD1 selectively in neurons
developed ALS (Jaarsma et al. 2008). In another study, disease onset in
chimeric SOD1G37R mice was accelerated when mSOD1 was present in cells
other than motor neuron cells (Yamanaka et al. 2008). Conversely, the
presence of wild-type non-neuronal cells substantially delayed disease onset
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in chimeric SOD1G37R and SOD1G85R mice (Clement et al. 2003, Yamanaka
et al. 2008). Similarly, in transgenic SOD1G93A mice, wild-type microglia
slowed motor neuron loss and prolonged disease duration and survival
compared to mice possessing mSOD1 expressed microglia (Beers et al.
2006). Together, these findings clarify that the presence of mSOD1 promotes
motor neuron loss by both cell and non-cell autonomous processes in
transgenic mSOD1 mice.
Following motor neuron death, mSOD1 aggregates are released into the
extracellular environment to provide a positive feedback loop to further
induce motor neuron death (Brundin et al. 2010). These extracellular
mSOD1 aggregates are not directly toxic to motor neurons, but rather
activate microglia, which then mediate neurotoxicity. SOD1 aggregates in
the extracellular space are taken up by neighbouring cells via
micropinocytosis or in association with vesicles (Zeineddine and Yerbury
2015; Silverman et al. 2016). In vitro studies have demonstrated that the
extracellular mSOD1 cause detectable injury to motor neurons when
co-cultured with microglia, but had no effect on motor neurons in the
absence of microglia (Zhao et al. 2010).
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1.1.3 Dual role of activated microglia in ALS
Microglia are the resident macrophages of the central nervous system (CNS).
Microglia are a highly dynamic population surveying the microenvironment
with extremely motile processes, which take part in the innate immune
response (Nimmerjahn et al. 2005, Cherry et al. 2014). In response to
damage or injury, microglia become activated, inducing their migration to
the site of injury, proliferation and causing the release of damage-associated
molecular patterns, cytokines, chemokines and reactive nitrogen and oxygen
species to promote neuroinflammation (Becher et al. 2017). It is generally
considered that activated microglia exhibit two different phenotypes in ALS,
M1 and M2 phenotypes (Parisi et al. 2016, Geloso et al. 2017), although this
concept remains controversial and is considered an over-simplification
(Ransohoff 2016). In ALS, microglia possess early protective M2 phenotype
characterised by small cell bodies with shorter and simple processes, and late
neurotoxic M1 phenotype exhibiting large cell bodies with short and
extensively branched processes (Ohgomori et al. 2016).
The dual role of ALS-related microglia has been demonstrated when
mSOD1 expressed M2 microglia isolated from ALS mice at disease onset
protected co-cultured motor neurons. On the other hand, mSOD1 expressed
M1 microglia isolated from ALS mice at disease end-stage damaged
co-cultured motor neurons (Liao et al. 2012). The activation of microglia

9

(microgliosis) and subsequent neuroinflammation is a major cause of fALS
(Hooten et al. 2015), although it remains unknown if a similar mechanism is
a major cause of sALS In humans, increased microgliosis has been
demonstrated in the spinal cords of specimens from ALS patients (Yiangou
et al. 2006). Microgliosis occurs specifically with motor neuron injury in the
motor cortex, along the corticospinal tract, and in the ventral horn of the
spinal cord (Philips and Robberecht 2011).
During early phases of disease, M2 phenotype possess a protective response
against signals triggered by motor neuron damage. M2 phenotype release
anti-inflammatory cytokines and neurotrophic factors including interleukin
(IL)-4, IL-10, IL-13, and insulin-like growth factor-1 to promote motor
neuron survival (Du et al. 2016; Tang and Le 2016). Consistently, in
SOD1G93A and SOD1G37R mice, overexpression of anti-inflammatory IL-10
have been demonstrated at the pre-onset phase of disease progression
(Gravel et al. 2016). An anti-inflammatory cytokine, IL-4, has also been
shown to suppress the release of reactive oxygen species and nitric oxide,
and

protected

co-cultured

primary

motor

neurons

against

microglia-mediated motor neuron damage (Zhao et al. 2006).
Despite, the actual processes that transform protective microglia into a toxic
form is still unknown, it is believed that the prolonged period of microglial
activation will transform protective M2 phenotype into deleterious M1
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phenotype. M1 phenotypes promote the release of pro-inflammatory factors
such as IL-1α, IL-1β, IL-6, IL-12, IL-23 and tumor necrosis factor (TNF)-α,
chemokines, prostaglandin E2, chemokine (C-C motif) ligand 2, ROS and
inducible nitric oxide synthase to proliferate motor neuron death (Hooten
et al. 2015, Du et al. 2016, Geloso et al. 2017). Furthermore, the death of
motor neurons results in the release of mSOD1 to provide a positive
feedback loop to further induce microglia-mediated motor neuron death
(section 1.1.2.2) (Figure 1.3).

mSOD1

Activated microglia
(M2 phenotype)

Anti-inflammatory
cytokines

Activated microglia
(M1 phenotype)

Prolonged
stimulation

Pro-inflammatory
cytokines

Extracellular mSOD1

Accelerates

Motor neuron repaired

Motor neuron death
Motor neuron impaired

Figure 1.3 Dual role of microglia in amyotrophic lateral sclerosis (ALS). Findings
from numerous studies suggest that mutant SOD1 (mSOD1) in neuron initiate toxic
actions which in combination with microglia possessing mSOD1 accelerates motor
neuron death. During the initial stages, M2 phenotype possesses protective response by
releasing anti-inflammatory cytokines in response to signals triggered by motor neuron
damage. Then, the prolonged period of microglial stimulation will transform protective
M2 phenotype into deleterious M1 phenotype and promotes release of pro-inflammatory
factors which accelerate motor neuron death. Furthermore, the death of motor neurons
results in mSOD1 release to provide a positive feedback loop to further induce
microglia-mediated motor neuron death. Figure adapted from Geloso et al. 2017.
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Thus, the dual role of microglia in ALS is well established. The modulation
of microglial function serves as a promising therapeutic strategy. However
detailed understanding of molecular mechanisms involved in microglial
activation and identification of molecular players that trigger microglial
activation is necessary. The P2X7 receptor, present on the surface of
microglia and which modulates microglial activation and proliferation is one
such molecular player (Monif et al. 2010).
1.2 The P2X7 receptor
The P2X7 receptor is a purinergic receptor that belongs to the P2X family
and is encoded by the P2RX7 gene (Coddou et al. 2011). The major
contribution of the P2X7 receptor in inflammation makes this receptor a
promising target in many inflammatory diseases including inflammation in
neurodegenerative diseases (Burnstock 2016, Adinolfi et al. 2018).
1.2.1 The P2X7 receptor structure
The P2X7 receptor is a trimeric ion channel that allows the rapid influx of
sodium and calcium ions and efflux of potassium ions following activation
by extracellular adenosine 5’-triphosphate (ATP) (Sluyter 2017a). Each
P2X7 subunit is made up of 595 amino acid residues consisting a large
extracellular loop, two transmembrane (TM) domains, and cytoplasmic
amino- and carboxy-terminal tails. The unique feature of this receptor is the
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presence of long cytoplasmic carboxy-terminal tail which is 239 amino acid
long (Sluyter 2017a). Based initially on the crystal structure of the zebrafish
P2X4 receptor (Kawate et al. 2009), the P2X7 subunit is often compared to
the shape of a dolphin. In this comparision, the two transmembrane domains
represent the dolphin fluke and the different segments of the large
extracellular loop represent the head, flippers and dorsal fin of the dolphin
(Di Virgilio et al. 2017) (Figure 1.4). This extracellular loop contains five
cysteine amino acid pairs to form five disulphide bridges (Lenertz
et al. 2010) (Figure 1.4).

Extracellular
loop

A

B

TM2

Extracellular

TM1
TM1

TM2

Intracellular
NH2
COOH

Figure 1.4 The P2X7 receptor subunit. (A) Each P2X7 subunit is made up of 595 amino
acid residues consisting of a large extracellular loop, two transmembrane domains (TM1
and TM2), and cytoplasmic amino- and carboxy-terminal. Three P2X7 subunits
oligomerise to form the P2X7 receptor (not shown) (B) The structure of P2X7 subunit is
often compared to the shape of a dolphin, where the two transmembrane domains
represent the dolphin fluke and the different segments of the large extracellular loop
represent head, flippers and dorsal fin of the dolphin body. Figures adapted from
Di Virgilio et al. 2017 and Di Virgilio et al. 2018.
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The crystal structures of the human P2X3 receptor (Mansoor et al. 2016),
zebrafish P2X4 receptor (Hattori and Gouaux 2012) and panda P2X7
receptor (Karasawa and Kawate 2016) provide insight on the agonist and
antagonist binding sites of the P2X7 receptor. Computer modelling indicates
that the binding site for ATP is located at the intersection of the extracellular
loops of two neighboring subunits (Jiang et al. 2013). The P2X7 receptor is
different from other P2X receptors, requiring relatively high concentrations
of extracellular ATP for activation, with a half maximal effective
concentration (EC50) of 100-300 µM (Jarvis and Khakh 2009). The reason
for this low affinity for ATP is explained by sequence differences and the
tertiary structure of the entrance of the ATP-binding pocket. In the P2X7
receptor, the ATP binding pockets are narrow in shape and lack positively
charged amino acid residues at its entrance, making it difficult for
hydrophilic compounds such as ATP to enter and bind (Di Virgilio et al.
2017). Upon entry of ATP into this pocket, phosphate groups of ATP bind
several charged amino acid residues (Lys64, Lys66, Lys193, Arg294, and
Lys311), whilst the adenine moiety of ATP interacts with a threonine residue
(Thr189) present at the bottom of the binding pocket (Di Virgilio et al. 2017).
The crystal structure of the panda P2X7 receptor revealed an
antagonist-binding pocket site distinct from the ATP-binding pocket, but
also located in a groove formed between two neighbouring subunits. This
study identified that five structurally different P2X7 receptor antagonists
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(including JNJ-47965567 which is used in this thesis) bound this pocket.
Upon activation by ATP, the P2X7 receptor undergoes conformational
changes, which narrows this inter-subunit space and drug-binding pocket.
Binding of allosteric antagonists in the drug-binding pocket prevents the
constriction of inter-subunit space and modulates ATP-binding site, thereby
preventing P2X7 receptor activation (Karasawa and Kawate 2016).
The P2X7 receptor, in the absence of extracellular ATP, can mediate
phagocytosis of dying or dead cells (see Section 1.2.5). Notably, specific
P2X7 antagonists fail to impair P2X7 receptor-mediated phagocytosis (Ou
et al. 2018). This indicates that if the central role of the P2X7 receptor in a
given mechanism or disease state is related to its phagocytic function rather
than its channel function, then the use of specific P2X7 antagonists may fail
to reveal a role for this receptor or establish its value as a therapeutic target
including in animal studies.
1.2.2 Macropore formation by the P2X7 receptor
A typical functional feature of the P2X7 receptor activation is opening of a
pore which allows uptake of large molecules up to ~900 Da (Yan et al. 2010).
The macropore allows the transport of large organic cations including
ethidium+, N-methyl-D-glucamine+ and YO-PRO-12+ across the plasma
membrane (Jarvis and Khakh 2009). The long carboxy-terminus of the P2X7
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receptor subunit is needed to generate the macropore. Initially, it was shown
that truncation of the carboxy-terminal of the rat P2X7 receptor at amino
acid residue 418 abolished macropore formation (Surprenant et al. 1996).
Further studies in which the carboxyl-terminal tail of the P2X7 receptor was
modified or truncated confirmed the importance of this region to macropore
formation (Smart et al. 2003, Sun et al. 2013, Mansoor et al. 2016).
Moreover, membrane cholesterol has been shown to modulate P2X7
receptor macropore formation via the carboxyl-terminal tail. The P2X7
receptor is associated with cholesterol rafts in the plasma membrane and its
carboxy-terminal tail is palmitoylated (Gonnord et al. 2009). During
macropore formation, this palmitoylated carboxy-terminal tail is inserted
into the plasma membrane, thus preventing cholesterol interaction with the
P2X7 receptor and allows the formation of macropore (Karasawa et al.
2017).
1.2.3 Distribution of the P2X7 receptor
P2X7 receptors are distributed widely in blood and the brain. Blood cells
such as monocytes, macrophages, dendritic cells, lymphocytes and
erythrocytes express P2X7 receptors (Di Virgilio et al. 2001). In the brain,
the P2X7 receptor is expressed abundantly on microglia as well as on
astrocytes, oligodendrocytes and Schwann cells (Skaper et al. 2006,
Sperlágh et al. 2006). Of note, a number of glial cell lines have been used to
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understand the function of P2X7 receptors in these cells. Our laboratory for
example, has previously used murine EOC13 microglial cell line to
demonstrate that P2X7 receptor activation on these cells can mediate
production of reactive oxygen and nitrogen species, as well as the death of
these cells (Bartlett et al. 2013). Thus, such cell lines remain useful tools to
study P2X7 receptors.
The presence of P2X7 receptors on neuronal cells is controversial. The P2X7
receptor has been identified in the cerebral cortex, hippocampus, brainstem,
spinal cord and at neuromuscular junctions (Weisman et al. 2012). Several
reports have also established the presence of P2X7 receptor on cultured
motor neurons (Gandelman et al. 2013, Franco et al. 2013). Surprisingly,
some reports have shown that P2X7 receptor antibodies stain hippocampal
structures within P2X7 receptor knock out mice (Sim et al. 2004), and the
presence of functional P2X7 receptor in the synaptosomes of those mice
(Sánchez-Nogueiro et al. 2005, Marín-García et al. 2008) create doubts on
the presence of neuronal P2X7 receptors. These results however may be due
to the presence of functional splice variants, which may have escaped
deletion in these mice (Illes et al. 2017). Thus, further research is required
to confirm the existence of neuronal P2X7 receptors.
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1.2.4 The P2X7 receptor as a cytotoxic receptor
One of the intriguing features of the P2X7 receptor is its ability to mediate
ATP-induced cell death. P2X7-mediated cell death depends on cell type,
agonist concentration and duration of activation (Di Virgilio et al. 1989).
The P2X7 receptor can mediate either necrosis or apoptosis, and is
associated with rapid blebbing of the plasma membrane (Wilson et al. 2002,
Savio et al. 2018). Previously, P2X7-mediated cell death has been described
in lymphocytes (Taylor et al. 2008), macrophages (Liu et al. 2010), leukemic
cells (Salaro et al. 2016), mesengial cell (Schulze-Lohoff et al. 1998) and in
microglia (Ferrari et al. 1997, He et al. 2017).
1.2.5 The P2X7 receptor as a phagocytic receptor
Another intriguing feature of the P2X7 receptor is that, in the absence of
extracellular ATP, this receptor can serve as a phagocytic receptor of dying
or dead cells potentially promoting inflammation and immunity. Studies
have shown that P2X7 receptors on human monocytes or monocyte-derived
macrophages,

murine

macrophages

or

astrocytes,

or

HEK-293

heterologously expressing P2X7 receptors possess phagocytic activity (Gu
et al. 2010, Gu et al. 2011, Yamamoto et al. 2013, Perez-Flores et al. 2016).
Moreover, these studies demonstrated P2X7 receptors, in the absence of
extracellular ATP, can mediate the phagocytosis of non-opsonised beads,
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heat-killed bacteria, and apoptotic lymphocytes or neuronal cells. In contrast,
the presence of extracellular ATP can prevent this process both in vitro and
in vivo (Gu et al. 2010). Serum glycoproteins can also inhibit P2X7
receptor-mediated phagocytosis of apoptotic lymphocytes and neuronal cells
by human monocyte-derived macrophages, whereas cerebrospinal fluid in
the CNS (which is devoid of glycoproteins) do not affect this process (Gu
et al. 2012). Collectively, these studies suggest that P2X7 receptor-mediated
phagocytosis could play (undefined) roles in preventing or promoting
neuroinflammatory conditions, including ALS.
1.3 The P2X7 receptor in ALS
Purinergic signalling is the combined action of extracellular nucleosides and
nucleotides, purinergic receptors and extracellular ectoATPases (Volonte
et al. 2011). This signalling pathway plays an important role in
neurodegeneration, neuroprotection and neuroregeneration in the CNS
(Burnstock 2016), including neurological diseases with motor symptoms
(Oliveira-Giacomelli et al. 2018). Moreover, purinergic signalling molecules
and pathways, especially the ATP-P2X7 receptor signalling axis is important
in the development of ALS (Volonte et al. 2016). The remainder of this
chapter will review the contribution of P2X7 receptors in ALS.
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1.3.1 The P2X7 receptor on microglia
The P2X7 receptor on microglia is thought to drive the progression of ALS.
P2X7 receptor overexpression is sufficient to drive microglial activation in
rat primary hippocampal cultures in the absence of pathological conditions
(Monif et al. 2009). Moreover, P2X7 receptor activation promotes
microglial stimulation, proliferation, and release of proinflammatory
cytokines such as TNF-α and IL-1β, causing neuroinflammation and cell
death (Volonte et al. 2012). In spinal cords from ALS patients, the
upregulation of P2X7 receptor and microgliosis have been reported
(Yiangou et al. 2006), supporting the concept that P2X7 receptor may cause
neurodegeneration through microglial activation in ALS in humans. The
P2X7 receptor is also upregulated in the spinal cord of SOD1G93A rats
(Casanovas et al. 2008) and in microglia from SOD1G93A mice (D'Ambrosi
et al. 2009). Moreover, this latter study showed that activation of the P2X7
receptor on mSOD1 microglia caused an increase in TNF-α and
cyclooxygenase-2, exerting toxic effects on neuronal NSC-34 and SH-SY5Y
cell lines (D'Ambrosi et al. 2009).
P2X7 receptor activation on microglia can also contribute to oxidative stress
in ALS. (Cozzolino et al. 2012). In vitro studies demonstrated P2X7 receptor
activation in microglia induced co-cultured neuronal cell death via
production of reactive oxygen and nitrogen species (Skaper et al. 2006,
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D’Ambrosi et al. 2009), whilst P2X7 receptor activation on SOD1G93A
microglia by 2’-3’-O-(benzoyl-benzoyl) ATP increases the assembly and
activity of NADPH oxidase-2 (Apolloni et al. 2013b). NADPH oxidase-2 is
an enzyme responsible for the production of intracellular and extracellular
reactive oxygen species, which can destroy motor neurons (Block 2008).
Finally, a role for P2X7 receptor activation of microglia in ALS is indirectly
supported by activities of ectoATPases. EctoATPases are the enzymes which
degrade

nucleoside

triphosphates

into

nucleoside

diphosphates,

monophosphates, nucleosides and other derivatives (Sebastian-Serrano et al.
2014), which in turn regulates the potential activities of purinergic receptors
(Yegutkin

2008).

The

main

ectoATPases

include

ectonucleotide

triphospho-diphosphohydrolase-1 (CD39), ectonucleotide pyrophosphatase
phosphodiesterases,

tissue

non-specific

alkaline

phosphatase

phosphomonoesterase and ecto-5'-nucleotidase (CD73) (Sebastian-Serrano
et al. 2014). CD39 is abundantly expressed on leukocytes and smooth muscle
cells (Yegutkin 2014). In the CNS, CD39 is expressed only on microglia but
not on astrocytes and neurons (Braun et al. 2000). Data indicates an
important role for the down-regulation of CD39 in ALS. Microglia from
SOD1G93A mice have a reduced extracellular ATP hydrolyzing activity
compared to microglia from wild-type mice (D’Ambrosi et al. 2009).
Consistent with this observation, CD39 mRNA expression is reduced in
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microglia from the spinal cords of SOD1G93A mice compared to wild-type
mice (Butovsky et al. 2015). Thus, reduced microglial CD39 expression in
ALS may lead to higher extracellular ATP concentrations and increased
P2X7 receptor activation to promote disease.
1.3.2 The P2X7 receptor on astrocytes
P2X7 receptor activation on astrocytes can promote ALS. Astrocytes, in
addition to microglia, produce proinflammatory cytokines and reactive
oxygen and nitrogen species (Barbeito et al. 2004). Additionally, activated
microglia can secrete cytokines to induce so-called A1 astrocytes, which are
abundant in the CNS of ALS patients and can induce the death of neurons
(Liddelow et al. 2017). Notably, SOD1G93A mutant astrocytes play important
roles in both neuroinflammation and motor neuron death in ALS (Nagai
et al. 2007). Moreover, P2X7 receptor activation on SOD1G93A mutant
astrocytes causes the production of neurotoxic factors and subsequent death
of motor neurons (Gandelman et al. 2010).
1.3.3 The P2X7 receptor mediates disease progression in ALS mice
The role of the P2X7 receptor in the progression of ALS has been examined
in three studies using the P2X7 antagonist Brilliant Blue G (BBG) in
SOD1G93A mice. In the first study, treatment of SOD1G93A mice with
45.5 mg/kg BBG intraperitoneally (i.p) after onset (first sign or symptom)
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improved motor coordination and weight loss. The delay in weight loss was
also greater in male than female mice (Cervetto et al. 2013). In the second
study, administration of 50 mg/kg BBG (i.p) in SOD1G93A mice from late
pre-onset improved motor coordination whereas administration of
250 mg/kg BBG (i.p) from late pre-onset delayed disease onset, improved
motor coordination and clinical scores in SOD1G93A mice. BBG treatment
(250 mg/kg) from late pre-onset also reduced motor neuron loss,
microgliosis and pro-inflammatory markers. The same doses of BBG
however had no effect when administered from asymptomatic and pre-onset
stages (Apolloni et al. 2014). Finally, in the third study conducted in our
laboratory, administration of 45.5 mg/kg BBG (i.p) at late pre-onset delayed
weight loss and extended survival in female SOD1G93A mice (Bartlett et al.
2017). In contrast to the studies with BBG, genetic ablation of the P2X7
receptor in SOD1G93A mice observed anticipated and worsened disease onset;
increased microgliosis, astrogliosis, motor neuron loss, activation of
NADPH oxidase 2 and stimulation of the downstream signalling pathway
(Apolloni et al. 2013a). These findings together with the positive outcomes
demonstrated by P2X7 receptor blockade with BBG treatment at different
stages of disease, suggest a complex role for the P2X7 receptor in ALS.
Moreover, these studies suggest that P2X7 receptors possess a
neuroprotective role, at least during the pre-symptomatic stages of the
disease, which may be related to beneficial (but unknown) events
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downstream of P2X7 receptor activation and/or via scavenging of dead cells
in the absence of extracellular ATP. On the other hand, the therapeutic
potential of the P2X7 receptor may be enhanced if treatment is commenced
in the initial symptomatic stages of disease. If we consider the detrimental
effect of P2X7 receptor may have on microglial activation, the dual role of
microglia also supports a neuroprotective or scavenging role of P2X7
receptor in the asymptomatic stages, and a neurodegenerative role in the
symptomatic stages of ALS.
Despite BBG supporting a role for the P2X7 receptor in ALS progression,
the effect of BBG was small. The limited effect of BBG in SOD1G93A mice
may be because BBG has recently been reported as a relatively poor
CNS-penetrant P2X7 antagonist. The administration of BBG at 50 mg/kg in
rats detected low concentrations of BBG in the brain (~13-22 ng/mL)
compared to plasma (~2000 ng/mL) (Bhattacharya and Biber 2016). Since
BBG is a blue color dye, the examination of BBG colour either
macroscopically or microscopically have also indicated the poor
CNS-penetration of BBG with extensive BBG colouration in peripheral
tissues (including skin, liver and spleen) but not in the brains or spinal cords
of ALS mice treated with BBG (Sluyter et al. 2017b). Thus, the role and
therapeutic potential of the P2X7 receptor in ALS could be demonstrated
using

CNS-penetrant

P2X7

antagonists

such

as

JNJ-47965567
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(Bhattacharya et al. 2013). JNJ-47965567 has been previously demonstrated
therapeutic

efficacy

in

rodent

models

of

temporal

lobe

epilepsy (Jimenez-Pacheco et al. 2016) and in neuropathic pain
(Bhattacharya et al. 2013)
1.4 Overview
Despite the limited effect of BBG in SOD1 mice, a role for the P2X7 receptor
in ALS progression can be proposed. It is hypothesized that mSOD1 within
motor neurons initiate motor neuron damage. The death of motor neurons
promotes extensive release of ATP which aggravates the activation of P2X7
receptor present on the surface of microglia and astrocytes to release
cytotoxic factors which, in turn accelerate motor neuron death. In parallel,
the presence of low level of CD39 on microglial surface maintains the high
extracellular concentration of ATP to activate P2X7 receptors (Figure 1.5).
1.5 Summary and research aims
ALS is a complex, progressive and fatal motor neuron disease. Despite
having tremendous knowledge in disease mechanisms leading to ALS, the
challenge remains to identify potential therapeutic targets in ALS. Among
different factors contributing to the progression of ALS, the involvement of
ATP-P2X7 signalling axis plays a role in this disease through the activation
of microglia and astrocytes to promote death of motor neurons. In order to
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Figure 1.5 Proposed mechanism for P2X7 receptor-mediated progression of motor
neuron death in amyotrophic lateral sclerosis (ALS). It is hypothesized that mutant
SOD1 (mSOD1) within motor neurons initiate motor neuron damage. The death of motor
neurons promotes extensive release of ATP which aggravates the activation of P2X7
receptor present on the surface of the microglia and astrocytes to release cytotoxic factors
and accelerate motor neuron death. The presence of low level of CD39 on the microglial
surface maintains a high extracellular concentration of ATP to activate P2X7 receptors.

understand the roles of the ATP-P2X7 signalling axis in ALS, cellular
models that closely resembles ALS-associated models would be beneficial
to establish. Furthermore, the use of CNS-penetrant P2X7 antagonists might
further establish the role of the P2X7 receptor in ALS progression in vivo.
Thus, this study aims to investigate the P2X7 receptor and CD39 on murine
EOC13 microglia to determine if it may serve as a suitable in vitro model of
these molecules on microglia in ALS. Additionally, this study also seeks to
determine if CNS-penetrant P2X7 antagonists JNJ-47965567 ameliorates
disease progression in SOD1 ALS mice.
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Chapter 2
Murine EOC13 microglia:
a potential model of motor neuron
disease-associated microglia
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2.1 Background
2.1.1 Contribution of microglia in amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a complex, progressive and fatal
motor neuron disease (Boillee et al. 2006). Microglia, the resident
macrophages of the central nervous system (CNS), play a crucial role in
neuroinflammation to promote motor neuron loss in ALS (Hooten et al.
2015). Increased microgliosis has been observed in spinal cords of ALS
patients (Yiangou et al. 2006). In ALS, the dual role of microglia is well
established. In ALS mice, mutant SOD1 (mSOD1) expressing M2 microglia
isolated at disease onset protected co-cultured motor neurons, whilst mSOD1
expressing M1 microglia isolated at disease end-stage damaged co-cultured
motor neurons (Liao et al. 2012). Thus, the modulation of microglial
function serves as a promising therapeutic strategy in ALS.
2.1.2 Role of ATP-P2X7 mediated microglial activation in ALS
progression
The P2X7 receptor is a trimeric ion channel that allows the flow of ions
following activation by extracellular adenosine 5’-triphosphates (ATP)
(Sluyter 2017a). P2X7 receptor is expressed abundantly on microglia
(Skaper et al. 2006). Our laboratory has previously demonstrated the
presence of P2X7 receptor on EOC13 murine microglial cell line (Bartlett
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et al. 2013). This receptor is upregulated in spinal cords from ALS patients
and SOD1G93A rats, and in microglia from SOD1G93A mice (Yiangou et al.
2006, Casanovas et al. 2008, D'Ambrosi et al. 2009). The ATP-P2X7
receptor signalling axis is important in the development of ALS. P2X7
receptor activation promotes microglial stimulation, proliferation, and
release of proinflammatory cytokines such as tumor necrosis factor
(TNF)-α, interleukin (IL-1β) and reactive oxygen species causing
neuroinflammation and motor neuron death in ALS (Volonte et al. 2016).
Ectonucleotide triphospho-diphosphohydrolase-1 (CD39) is an ectoATPase
that degrades extracellular ATP into adenosine 5’-diphosphate and
adenosine 5’-monophosphate (Sebastian-Serrano et al. 2014). As such,
increased CD39 expression negatively regulates P2X7 receptor activation in
various cell types including macrophages (Lévesque et al. 2010). Of note,
microglia from SOD1G93A mice have reduced ectoATPase activity and
Entpd1 mRNA expression (Entpd1 which encodes for CD39) compared to
microglia from wild-type mice (D’Ambrosi et al. 2009, Butovsky et al.
2015). Combined, these data indicate that CD39 expression and activity in
microglia is down-regulated in ALS, which may contribute to increased
P2X7 activity in these cells in this disease. Consistent with this, P2X7
activity is increased in microglia from SOD1G93A mice compared to
microglia from wild-type mice (D’Ambrosi et al. 2009). Thus,
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ALS-associated microglia can be defined as P2X7 receptor high but CD39
low cells.
2.1.3 Aims
Our group has previously shown, using flow cytometric techniques and
immunoblotting, that the murine EOC13 microglia cell line expresses a high
amount of functional P2X7 receptor (Bartlett et al. 2013). However, the
presence of CD39 or ectoATPase activity on these cells remains unknown.
Thus, this study aimed to confirm the presence of P2X7 receptor on EOC13
cells, and to determine the relative CD39 expression and ectoATPase activity
on these cells. These data will address whether EOC13 cells may serve as a
potential in vitro model of these molecules on ALS-associated microglia.
2.2 Materials and Methods
2.2.1 Reagents
Dulbecco’s Modified Eagle’s/F12 medium (DMEM/F12), GlutaMAX,
0.05% trypsin-ethylenediaminetetraaceticacid (EDTA), Rosewell Park
Memorial

Institute-1640

ammonium-chloride-potassium

(RPMI-1640)
(ACK)

lysing

buffer,

medium,
Dulbecco’s

phosphate-buffered saline (PBS), 100x HaltTM protease inhibitor single-use
cocktail, and SuperSignal West Pico Chemiluminescent Substrate were from
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ThermoFisher Scientific (Waltham, MA, USA). Fetal bovine serum (FBS)
(heat inactivated before use) was from Bovogen Biologicals (East Keilor,
Australia). β-Mercaptoethanol, ATP, 2-(hydroxypropyl)-beta-cyclodextrin
(β-CD) and bovine serum albumin (BSA) were from Sigma-Aldrich
(St.

Louis,

MO,

USA).

Phenylmethylsulfonylfluoride

(PMSF),

dithiothreitol (DTT), ethidium bromide, Triton X-100 and potassium
dihydrogen phosphate (KH2PO4) were from Amresco (Solon, OH, USA).
Agarose was from Bioline (London, UK). Protease inhibitor cocktail tablets
(complete, Mini, EDTA-free) were from Roche Diagnostics (Mannheim,
Germany). Precision Plus protein dual colour standards were from Bio-Rad
(Hercules, CA, USA). JNJ-47965567 was from Tocris Bioscience (Ellisville,
MO, USA). All other reagent grade chemicals and salts were from
Sigma-Aldrich or Amresco. Recipes for general solutions are listed in
Appendix A.
2.2.2 Antibodies
Rat anti-murine P2X7 monoclonal antibody (mAb) (clone 1F11), rat IgG2b
isotype control mAb (clone RTK4530), phycoerythrin (PE)-conjugated rat
anti-mouse CD39 mAb (clone Duha59), and PE-conjugated rat IgG2a
isotype control mAb (clone RTK2758) were from BioLegend (San Diego,
CA, USA). Allophycocyanin (APC)-conjugated donkey anti-rat IgG
antibody (Ab) was from eBioscience (San Diego, CA, USA). Purified rat
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anti-mouse CD16/CD32 mAb (clone 2.4G2) (Fc Block) was from BD
Bioscience (San Diego, CA, USA). Rabbit anti-mouse CD39 Ab (ab128666)
was from Abcam (Cambridge, UK). Rabbit anti-eukaryotic actin Ab
(A2066)

was

from

Sigma-Aldrich

(St.

Louis,

MO,

USA).

Peroxidase-conjugated goat anti-rabbit IgG Ab was from Rockland
Immunochemicals (Gilbertsville, PA, USA).
2.2.3 Cell lines
2.2.3.1 EOC13 microglia
The murine EOC13 microglial and murine LADMAC lymphoblastic cell
lines were obtained from the American Type Culture Collection (ATCC)
(Manassas, VA, USA) and cultured according to ATCC specifications.
EOC13 cells were maintained in DMEM/F12 supplemented with 10% FBS,
2 mM GlutaMAX (complete culture medium) and 20% LADMAC
conditioned medium (Appendix A) at 37oC and 95% air/5% CO2. When 90%
confluent, cells were harvested with 5 ml 0.05% trypsin-EDTA at 37oC and
95% air/5% CO2 for 5 min, followed by the addition of 10 ml of complete
culture medium. Any remaining adherent cells were removed by mechanical
scrapping and centrifuged for 5 min at 300 x g. Cells were sub-passaged 1:3
every 3-4 days.
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2.2.3.2 RAW 264.7 macrophages
The murine RAW 264.7 macrophage cell line was also originally obtained
from ATCC and cultured according to ATCC specifications. RAW 264.7
macrophages were maintained in complete culture medium at 37oC and
95% air/ 5% CO2. When 90% confluent, cells were harvested by mechanical
scrapping and centrifuged for 5 min at 300 x g. Cells were sub-passaged 1:10
every 3-4 days.
2.2.4 Spleen cells
A C57BL/6J mouse spleen (Australian BioResources, Moss Vale, Australia)
was kindly provided by Carlee Mottley (University of Wollongong,
Wollongong, Australia) under institutionally-approved shared animal tissue
arrangements. The spleen was mechanically dissociated in RPMI-1640
medium supplemented with 10% FBS. Spleen cells were then filtered
through a 70 µm strainer (Greiner Bio-one, Kremsmünster, Austria) and
incubated in ACK lysis buffer at room temperature for 5 min. Lastly, cells
were washed once with PBS containing 10% FBS (PBS/10%FBS) for 5 min
at 300 x g and resuspended in ice-cold PBS/10% FBS.
2.2.5 RNA isolation and reverse transcription polymerase chain reaction
RNA isolation from EOC13 cells and cDNA synthesis was carried out as
described (Geraghty et al. 2017). Harvested EOC13 cells were washed twice
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with PBS. Ribonucleic acid (RNA) was isolated from EOC13 cells using an
Isolate II RNA Mini Kit (Bioline, London, UK) according to the
manufacturer’s instructions. Isolated RNA was converted to complementary
DNA (cDNA) using qScript cDNA Synthesis Kit (Quanta Biosciences,
Gaithersburg, MD, USA) as per the manufacturer’s instructions and stored
at -20oC until use. cDNA synthesis was then checked by reverse transcription
polymerase chain reaction (RT-PCR) using primers to the housekeeping
gene Actb (ThermoFisher Scientific, Waltham, MA, USA). PCR was run at
95oC for 5 min followed by 35 cycles at 95oC for 30 s, 55oC for 30 s and
72oC for 1 min and then holding at 72oC for 8 min, 35oC for 3 min and at
4oC until samples were collected for further processing. cDNA originally
obtained from a BALB/c mouse spleen (Bartlett et al. 2017) was used as a
positive control, and was kindly provided by Debbie Watson (University of
Wollongong, Wollongong, Australia). The purity and size of amplicons were
confirmed by separating on a 1.5% agarose gel in Tris-acetate-EDTA buffer
(40 mM Tris, 20 mM acetic acid and 1 mM EDTA) and visualised using
ethidium bromide staining. Images of gels were collected using a Bio-Rad
Criterion Stain Free Imager and Image Lab Software (Bio-Rad, Hercules,
CA, USA).
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2.2.6 Quantitative real-time polymerase chain reaction
PCR amplification was performed as described (Geraghty et al. 2017).
Quantitative real-time polymerase chain reaction (qPCR) of cDNA was
conducted in triplicate and performed using TaqMan Universal Master Mix
II (ThermoFisher Scientific, Waltham, MA, USA) according to the
manufacturer’s instructions with primers for VIC labelled Gapdh
(Mm99999915_m1), FAM labelled P2rx7 (Mm01199503_m1) and
FAM-labelled Entpd1 (Mm00515447_m1) (ThermoFisher Scientific). Each
qPCR was run at 50°C for 2 min, followed by 95 °C for 10 min and,
40 cycles at 95°C for 15 s and 60°C for 1 min using a Quant Studio 5 RealTime PCR (ThermoFisher Scientific). Relative gene expression in each
sample was normalised to the housekeeping gene Gapdh and analysis was
conducted

using

Quanta

Studio

Design

and

Analysis

Software

(ThermoFisher Scientific). Relative gene expression in EOC13 cells is
presented relative to the corresponding gene in the BALB/c spleen.
2.2.7 Cell-surface P2X7 receptor expression by flow cytometry
Immunostaining of cell-surface P2X7 receptor was performed as described
(Bartlett et al. 2013). Harvested EOC13 cells were washed twice with
PBS/10% FBS. Cells (1x106 cells/200 µL/tube) were incubated with either
anti-P2X7 receptor or isotype control (rat IgG2b) mAb (0.5 mg/ml) on ice for
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30 min. Cells were then washed twice with 1 ml PBS/10% FCS (5 min at
300 x g) and incubated with APC-conjugated anti-rat IgG mAb (0.2 mg/ml)
on ice for 30 min protected from light. Cells were then washed once as above.
Events were collected using a LSR II flow cytometer (BD Biosciences) using
a 660/20 band-pass filter for APC. Relative expression, determined as mean
fluorescence intensity (MFI), and the percentage of P2X7 receptor positive
cells were determined using FlowJo Software version 8.7.1 (Tree Star,
Ashland, OR, USA).
2.2.8 P2X7 receptor activity
The activity of the P2X7 receptor on EOC13 cells was assessed using a
fixed-time ethidium+ uptake assay as described (Bartlett et al. 2013, Sluyter
and Vine 2016). Cells were washed three times in either sodium chloride
(NaCl) medium (140 mM NaCl, 5 mM NaOH, 5 mM KCl, 10 mM HEPES,
0.1% BSA and 5 mM glucose, pH 7.4) or physiological medium (147mM
NaCl, 2 mM KCl, 2mM CaCl2.2H2O, 1 mM MgCl2, 10 mM HEPES, pH 7.4).
Cells in either assay medium (5x105 cells/1ml) were incubated in the absence
or presence of 30% β-CD or 10 µM JNJ-47965567 at 37oC for 15 min.
Ethidium bromide (25 µM) was then added and cells incubated in the
absence or presence of 1 mM ATP at 37oC for 5 min. The assay was
terminated by the addition of an equal volume of ice-cold NaCl medium
containing 20 mM magnesium chloride (MgCl2) (MgCl2 medium) followed
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by centrifugation (5 min at 300 x g). Cells were washed once with
corresponding assay medium and events collected using a LSR II flow
cytometer using a 575/26 band-pass filter for ethidium+. The MFI of relative
ethidium+ uptake was determined using FlowJo Software version 8.7.1.
2.2.9 Cell-surface CD39 expression by flow cytometry
Harvested EOC13, RAW 264.7 and spleen cells were washed twice with
PBS/10%FCS (5 min at 300x g). Cells (1x105 – 1x106 cells/100 µL/tube)
were incubated with Fc Block (0.5 mg/ml) on ice for 10 min and then with
PE-conjugated anti-CD39 or isotype control (rat IgG2a) mAb (0.2 mg/ml) on
ice for 15 min protected from light. Cells were washed once as above
(section 2.2.7) and events were collected using a LSR II flow cytometer
using a 575/26 band-pass filter for PE. Relative expression was determined
as MFI, and the percentage of CD39 positive cells were determined using
FlowJo Software version 8.7.1.
2.2.10 CD39 expression by Western blotting
2.2.10.1 Cell lysates preparation
CD39 expression in EOC13 cell lysates was examined by Western blotting
as described (Bartlett et al. 2013). Harvested EOC13 cells were washed
twice with PBS. EOC13 cells in ice-cold lysis buffer (1% Triton X-100,
1 mM PMSF and complete EDTA-free protease inhibitor cocktail, 50 mM
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BisTris, 750 mM 6-aminohexanoic acid, pH 7.0) were sheared by passing
ten times through an 18 G needle and stored at -20oC.
2.2.10.2 Gel electrophoresis
For protein separation, cell lysates (section 2.2.10.1) were thawed and
centrifuged (16,000 x g for 10 min at 4°C). The total protein concentration
in each cell lysate supernatant was determined using the BCA Protein Assay
Kit (ThermoFisher Scientific) as per the manufacturer’s instructions
(Appendix B). Supernatants were mixed with 4 x SDS loading buffer
containing 10 mM DTT (Appendix A) and incubated at 94oC for 3 min.
Equal amounts of protein from each sample (20 µg/lane) and 10 µl Precision
Plus protein dual colour standards were separated by sodium dodecyl
sulphate

polyacrylamide

gel

electrophoresis

(SDS-PAGE)

on

Mini-PROTEAN TGX Precast Gels (Bio-Rad) following the manufacturer’s
instructions. After protein separation, equal protein loading was confirmed
by visualising stain-free gels with Stain Free Imager and Image Lab Software
(Bio-Rad).
2.2.10.3 Immunoblotting
Proteins were transferred to nitrocellulose membranes (Bio-Rad).
Membranes were blocked in Tris-buffered saline (TBS; 250 mM NaCl and
50 mM Tris, pH 7.5) containing 0.2% Tween-20 and 5% skim milk powder
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at room temperature for 2 h. Membranes were then incubated with
anti-CD39 (1:500) and anti-β-actin (1:1000) Ab in TBS/0.2% Tween-20/5%
skim milk overnight at 4oC. Membranes were then washed three times over
15

min

with

TBS/0.2%

Tween-20

and

then

incubated

with

peroxidase-conjugated anti-IgG (1:2000) Ab in TBS/0.2% Tween-20/5%
skim milk at room temperature for 1 h. Membranes were then washed as
above and visualised with SuperSignal West Pico chemiluminescent
substrate. Protein bands were imaged using the Amersham Imager
(GE Healthcare, Little Chalfont, Buckinghamshire, UK).
2.2.11 EctoATPase activity
The activity of ectoATPases on EOC13 cells was assessed by liberation of
phosphate from ATP using the molybdite assay as described (Mansfield and
Hughes 2014). EOC13 cells seeded in 12-well plates (2.6 x105 cells/
2 ml/well) were washed three times with phosphate-free buffer (20 mM
HEPES, 120 mM NaCl, 5 mM KCl, 10 mM Glucose, 2 mM CaCl2, 1.2 mM
MgSO4, pH 7.4) and then incubated with 100 µM ATP in phosphate free
buffer (0.5 ml/well) at 37oC in the waterbath for 10, 20, 30 or 60 mins.
Following each respective incubation, media aspirated and incubated with
equal volumes of colour reagent (1% ammonium molybdite, 0.3 M H2SO4,
4% FeSO4) at room temperature for 15 mins. The absorbance was then
recorded at 750 nm using a POLARstar Omega plate reader (BMG Labtech,
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Ortenberg, Germany). Phosphate concentration was determined relative to a
phosphate (KH2PO4) standard curve (Appendix B) assembled in GraphPad
Prism 5.0 (San Diego, CA, USA). Treatments were carried out in
quadruplate and the mean phosphate concentration in nmols per treatment
was determined.
For the quantification of total protein in each well of the 12-well plates after
aspirating media above, cells were lysed by 3 days incubation with NaOH
(0.5 ml/well) at 4oC. Cell lysates were mixed with equal volume of Lowry
reagent (2% NaOH, 0.81 M NaCO3, 1% CuSO4, 7mM Na-k Tartrate) and
incubated with 0.03 ml Folin’s reagent (1:2 in H2O) at room temperature for
10 min. The absorbance was recorded at 750 nm in a SPECTROStar Nano
plate reader (BMG Labtech, Ortenberg, Germany). Total protein
concentration was determined relative to a BSA standard curve
(Appendix B). Estimates of protein concentration for each sample and
standard were performed in duplicate. The phosphate concentrations (nmols)
determined above were then normalized to the protein concentration in
corresponding samples (µg) and presented as nmols phosphate/µg protein.
2.2.12 Data analysis
All analyses were performed using GraphPad Prism 5.0. Data are presented
as mean ± standard deviation (SD). Differences between multiple treatments
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were compared using a two-way ANOVA with a Bonferroni post-hoc test.
Statistical differences were considered significant when P < 0.05.
2.3 Results
2.3.1 Quality control of cDNA from EOC13 cells
To determine the quality of cDNA reverse transcribed from RNA of EOC13
cells, cDNA was amplified by PCR using primers to the housekeeping gene
Actb which codes for β-actin. cDNA from mouse splenocytes (Petry et al.
2001) was used as a positive control (and as a reference gene for P2rx7 and
Entpd1 gene expression below). Amplified cDNA of three individual
EOC13 cell samples were found to yield amplicons approximately 280 base
pairs (bp) in size, similar to cDNA of mouse splenocytes. Water, in place of
cDNA, was used as a negative control and yielded no bands (Figure 2.1).
2.3.2 Expression and function of the P2X7 receptor in EOC13 cells
2.3.2.1 EOC13 cells express the P2X7 receptor
EOC13 cells express functional P2X7 receptor (Bartlett et al. 2013),
however the expression of P2rx7 mRNA has never been reported. To
investigate this in EOC13 cells, qPCR of cDNA was performed using
primers to the P2rx7 gene. P2rx7 gene expression for each sample was
normalised to the housekeeping gene Gapdh, with P2rx7 gene expression
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Figure 2.1 Quality control of cDNA from EOC13 cells. RNA was isolated from EOC13
cells or mouse spleen, reverse transcribed to cDNA and amplified by PCR using primers
to the housekeeping gene Actb. Water, in place of cDNA, was used as a negative control.
Amplicons were separated on a 1.5% agarose gel and visualised with ethidium bromide
staining. Marker represents Hyper Ladder II. EOC13 cells represent three independent
samples.

shown relative to splenic P2rx7 gene expression. The relative P2rx7
expression in EOC13 cells was approximately 21 times that of splenic P2rx7

Relative P2rx7 Expression
to Spleen P2rx7

expression (Figure 2.2).
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Figure 2.2 EOC13 cells express relatively high amounts of P2rx7 mRNA. cDNA from
EOC13 cells was analysed by qPCR using primers to P2rx7. P2rx7 gene expression was
normalised to Gapdh, with P2rx7 gene expression shown relative to splenic P2rx7 gene
expression. Data represents mean ± SD (n = 3).
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Cell-surface P2X7 receptors on EOC13 cells has been demonstrated by flow
cytometry using an anti-P2X7 mAb (clone HANO43) (Bartlett et al. 2013).
Since then, a second anti-P2X7 mAb (clone 1F11) has become available
(Kurashima et al. 2012). To examine the presence of cell-surface P2X7
receptors on EOC13 cells using this newer mAb, cells were labelled with an
isotype control or anti-P2X7 receptor (clone 1F11) mAb and analysed by
flow cytometry. The relative binding of mAb (MFI) was determined using
the gating strategy shown in Figure 2.3. The MFI of isotype control and
P2X7 receptor mAb binding was 3.6 ± 0.3 and 56.3 ± 26.5 respectively, with
a mean difference of 52.7 ± 26.2 (n = 3). Comparison of this histogram
revealed that 86.2 ± 14.13% of EOC13 cells were positive for the P2X7

SSC

FSC-H

receptor (Figure 2.3).

FSC-A

FSC

Figure 2.3 EOC13 cells express cell-surface P2X7 receptors. EOC13 cells were
incubated with isotype control or anti-P2X7 receptor (clone 1F11) mAb, followed by
incubation with APC-conjugated anti-IgG Ab and then analysed by flow cytometry. (Left
panel) Single, viable cells were first gated by forward scatter area (FSC-A) and forward
scatter height (FSC-H), and then (middle panel) FSC-A and side scatter area (SSC-A).
(Right panel) Histograms were used to determine anti-P2X7 receptor (red) and isotype
control (blue) mAb binding to the surface of EOC13 cells (n = 3). Marker region (as
shown) was used to determine the percentage of P2X7 receptor positive cells. Data is
representative of three independent experiments.
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2.3.2.2 EOC13 cells express functional P2X7 receptors
To confirm the presence of functional P2X7 receptors on EOC13 cells, an
ATP-induced ethidium+ uptake assay was performed in EOC13 cells
suspended in NaCl medium as described (Bartlett et al. 2013). EOC13 cells
in NaCl medium were pre-incubated at 37oC for 15 min in the absence or
presence of either β-CD or the P2X7 receptor antagonist, 10 µM
JNJ-47965567 in β-CD (Jimenez-Pacheco et al. 2016) and then in the
absence (basal) or presence of 1 mM ATP. Cells were gated as shown in
Figure 2.4. Cells incubated in the absence of ATP displayed typical forward
scatter (FSC) and side scatter (SSC) (Figure 2.4 A). However, incubation
with ATP caused a large reduction in the FSC of cells pre-incubated in the
absence of β-CD or JNJ-47965567, or in the presence of β-CD
(Figure 2.4 B). Notably, this decrease in FSC by ATP was partly prevented
by pre-incubation with JNJ-47965567 (Figure 2.4 B). This suggested that
ATP mediated the rapid death of some EOC13 cells during the course of the
assay. Nevertheless, cells remaining in the single, viable gate were analysed
for ethidium+ uptake.
In the absence of β-CD or JNJ-47965567, or presence of β-CD, ATP induced
high amounts of ethidium+ uptake into EOC13 cells compared to
corresponding cells incubated in the absence of ATP (basal). Pre-incubation
with JNJ-47965567 impaired ATP-induced ethidium+ uptake by 65.72 ±
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4.4% compared to ATP-induced ethidium uptake into cells incubated with
β-CD and ATP (P < 0.001). Ethidium+ uptake into cells incubated in the
absence of ATP was similar between all three treatments (Figure 2.4 C, D).
Due to the noticeable changes in FSC above (Figure 2.4), the experiment
was repeated using a new stock of NaCl medium to exclude the possibility
that the initial NaCl medium was the likely cause of such changes. Changes
in FSC, similar to above, were observed again in the new NaCl medium stock
(data not shown). Again, similar results were found when ATP induced
ethidium+ uptake into EOC13 cells pre-incubated in the absence of β-CD or
JNJ-47965567, or in the presence of β-CD (Figure 2.5). Whilst
pre-incubation with JNJ-47965567 reduced ATP-induced ethidium+ uptake
by 59.49 ± 3.8% compared to cells incubated with β-CD and ATP
(P < 0.001) (Figure 2.5).
The results above (Figure 2.4 and 2.5) suggest that P2X7 receptor activity is
causing the rapid ATP-induced death of the majority of EOC13 cells in NaCl
medium. This medium is normally free of calcium and magnesium ions,
which can impair P2X7 activation (Virginio et al. 1997, Yan et al. 2011).
Thus, the experiments above were repeated using EOC13 cells in a
physiological medium (Sluyter and Vine 2016), which contains 2mM Ca2+
and 1 mM Mg2+, and therefore partially limits P2X7 receptor activity and
possibly ATP-induced cell death. As expected, the FSC of EOC13 cells in
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Figure 2.4 EOC13 cells express functional P2X7 receptors. (A and B) EOC13 cells in
NaCl medium were pre-incubated in the absence (control) or presence of 30% (β-CD) or
10 µM JNJ-47965567 at 37oC for 15 min. Cells were then incubated with 25 µM
ethidium+ in the absence (basal) or presence of 1 mM ATP for a further 5 min. Incubations
were stopped by the addition of MgCl2 medium. Cells were gated as in Figure 2.3.
(C) Ethidium+ uptake was determined from histograms. Data is representative of three
independent experiments. (D) Results are shown as means ± SD (n = 3);
***
P < 0.001 compared to JNJ-47965567 and ATP.
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Figure 2.5 The P2X7 receptor antagonist JNJ-47965567 impairs ATP-induced
ethidium+ uptake in EOC13 cells suspended in a second stock of NaCl medium.
EOC13 cells in NaCl medium were pre-incubated in the absence (control) or presence of
30% (β-CD) or 10 µM JNJ-47965567 at 37oC for 15 min. Cells were then incubated with
25 µM ethidium+ in the absence (basal) or presence of 1 mM ATP for a further 5 min.
Incubations were stopped by the addition of MgCl2 medium. Cells were gated as in Figure
2.3 (data not shown). (A) Ethidium+ uptake was determined from histograms. Data is
representative of three independent experiments. (B) Results are shown as means ± SD
(n = 3); *** P < 0.001 compared to JNJ-47965567 and ATP.

physiological medium was largely unchanged by incubation with ATP
(Figure 2.6 A, B). Further, as expected ATP induced ethidium+ uptake into
EOC13 cells pre-incubated in the presence of β-CD (P < 0.05). In contrast,
pre-incubation with JNJ-47965567 reduced ATP-induced ethidium+ uptake
by 99.4 ± 0.6% compared to cells incubated with β-CD and ATP (P < 0.05)
(Figure 2.6 C, D).
2.3.3 Expression and function of CD39 in EOC13 cells
2.3.3.1 EOC13 cells express low amounts of CD39
The presence of CD39 on EOC13 cells has never been reported. To
investigate this in EOC13 cells, qPCR of cDNA was first performed using
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Figure 2.6 The P2X7 receptor antagonist JNJ-47965567 impairs ATP-induced
ethidium+ uptake in EOC13 cells suspended in a physiological medium. (A and B)
EOC13 cells in physiological medium were pre-incubated in the absence (control) or
presence of 30% (β-CD) or 10 µM JNJ-47965567 at 37oC for 15 min. Cells were then
incubated with 25 µM ethidium+ in the absence (basal) or presence of 1 mM ATP for a
further 5 min. Incubations were stopped by the addition of MgCl2 medium. Cells were
gated as in Figure 2.3. (C) Ethidium+ uptake was determined from histograms. Data is
representative of three independent experiments. (D) Results are shown as means ± SD
(n = 3); * P < 0.05 compared to JNJ-47965567 and ATP.
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primers to the Entpd1 gene (encoding CD39). Entpd1 gene expression for
each sample was normalised to the housekeeping gene Gapdh, with Entpd1
gene expression shown relative to splenic Entpd1 gene expression. The
relative Entpd1 expression on EOC13 cells was approximately 7% of splenic

Relative Entpd1 Expression
to Spleen Entpd1

Entpd1 expression (Figure 2.7).

0.10
0.08
0.06
0.04
0.02
0.00

EOC13

Figure 2.7 EOC13 cells express relatively low amounts of Entpd1 mRNA. cDNA from
EOC13 cells was analysed by qPCR using primers to Entpd1. Entpd1 gene expression
was normalised to Gapdh, with Entpd1 gene expression shown relative to splenic Entpd1
gene expression. Data represent mean ± SD (n = 3).

mRNA expression does not always reflect protein expression (Greenbaum
et al. 2003). Therefore, to confirm if CD39 expression is low on EOC13
cells, cells were labelled with an isotype control or anti-CD39 mAb and
analysed by flow cytometry. RAW 264.7 cells, which express cell-surface
CD39 (Liao et al. 2010) were used as a positive control. The relative mAb
binding (MFI) on EOC13 and RAW 264.7 cells was determined using the
gating strategy shown in Figure 2.8. The MFI of isotype control and CD39
mAb binding on EOC13 cells was 9.0 ± 2.2 and 14.2 ± 1.5 respectively, with
a mean difference of 5.16 ± 0.7 (n = 3). Comparison of this histogram
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revealed that 27 ± 25.35% of EOC13 cells were positive for CD39
(Figure 2.8 A). Unexpectedly, CD39 expression on RAW 264.7 cells was
absent. The MFI of isotype control and CD39 mAb binding on these cells
was 7.3 ± 1.1 and 6.5 ± 1.3 respectively, with a mean difference below 0
(n = 3) (Figure 2.8 B).
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Relative CD39 Expression (MFI)

FSC-A
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Figure 2.8 EOC13 cells express low amounts of cell-surface CD39. EOC13 and RAW
264.7 cells were incubated with PE-conjugated isotype control or anti-CD39
(clone Duha59) mAb, and then analysed by flow cytometry. (Left and middle panels)
Cells were gated as in Figure 2.3. (Right panels) Histograms were used to determine
anti-CD39 (red) and isotype control (blue) mAb binding to the surface of (A) EOC13
cells (n = 3) and (B) RAW 264.7 cells (n = 3). Marker region (as shown) was used to
determine the percentage of CD39 positive cells on EOC13 cells. Data is representative
of three independent experiments.

Given the unexpected findings with the anti-CD39 mAb and RAW 264.7
cells above (Figure 2.8), this mAb was checked on mouse splenocytes, as
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mouse splenic leukocyte populations can express CD39 (Zhou et al. 2009).
The relative CD39 expression (MFI) on mouse splenocytes was determined
by using the gating strategy shown in Figure 2.9. The MFI of isotype control
and CD39 mAb binding was 5.7 and 9.77 respectively, with a mean
difference of 4.07 and approximately 41.2% of these cells positive for CD39

Relative Cell Number

SSC

FSC-H

expression (n = 1) (Figure 2.9).

Relative CD39 Expression (MFI)

FSC-A

FSC

Figure 2.9 Mouse spleen express cell-surface CD39. Mouse splenocytes were
incubated with PE-conjugated isotype control or anti-CD39 (clone Duha59) mAb, and
then analysed by flow cytometry. (Left and middle panel) Cells were gated as in Figure
2.3. (Right panel) Histograms were used to determine anti-CD39 (red) and isotype control
(blue) mAb binding to the surface of splenocytes (n = 1). Marker region (as shown) was
used to determine the percentage of CD39 on splenocytes.

Finally, to confirm the absence or low expression of CD39 in EOC13 cells,
proteins in EOC13 cell lysates were separated by SDS-PAGE and transferred
to nitrocellulose membranes, and probed with an anti-CD39 Ab known to
detect mouse CD39 by this method (Rao et al. 2014). An anti-β-actin Ab was
used as a positive control. Sample loading was confirmed by the stain-free
gel (Figure 2.10 A). Probing of the membrane with anti-β-actin Ab revealed
the presence of a band at 43 kDa, corresponding to the molecular weight of
β-actin. However, no band corresponding to CD39 (57 kDa) or any other
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Figure 2.10 Absence of CD39 protein in EOC13 cell lysates. (A) EOC13 cell lysates
and molecular weight markers (Marker) were separated by SDS-PAGE and visualised by
stain-free imaging. (B) Separated proteins were then transferred to a nitrocellulose
membrane and probed with either an anti-CD39 or anti-β-actin Ab. (A,B) Images are
representative of three independent experiments.

2.3.3.2 EOC13 cells display low ectoATPase activity
CD39 and other ectoATPases can rapidly hydrolyse ATP, liberating nm
amounts of phosphate (Bulavina et al. 2013, Yegutkin 2014). Therefore, to
determine if EOC13 cells display ectoATPase activity, the capability of these
cells to liberate phosphate from ATP (ATP hydrolysis) was assessed by the
molybdite assay over time. Phosphate and total protein concentrations were
determined relative to phosphate and BSA standard curves, respectively
(Appendix B). Liberation of phosphate (ATP hydrolysis) from EOC13 cells
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after 10 min was minimal and variable. Phosphate liberation after 20 min
was minimal but slightly increased at 30 and 60 min. There were no
statistically significant differences between time points (Figure 2.11).
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Figure 2.11 EOC13 cells display low ectoATPase activity. EOC13 cells in phosphate
free buffer were incubated with 100 µM ATP at 37oC as indicated. Supernatants were
collected and mixed with colour reagent, and the absorbance read at 750 nm. Phosphate
concentrations were determined using a standard phosphate curve, normalized to total
protein present in the cells. Data is presented as mean nmols phosphate/µg protein ± SD
(n = 4).

2.4 Discussion
2.4.1 Summary of results
The current study confirms the abundant expression of functional P2X7
receptors on the surface of murine EOC13 microglia. This study also
revealed for the first time, negligible cell-surface expression of CD39 and
ectoATPase activity on these cells.
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2.4.2 EOC13 cells express high amounts of P2X7 receptors
The current study confirms the presence of cell-surface P2X7 receptors on
EOC13 cells. Moreover, the current study demonstrated for the first time that
these cells express P2rx7 mRNA and demonstrate the presence of
cell-surface P2X7 receptors on EOC13 cells, using a recently developed
anti-P2X7 receptor mAb (clone IF11) (Kurashima et al. 2012). Of note, the
amount of cell-surface P2X7 detected by this mAb is greater than that
previously observed in our laboratory with an alternate mAb (HANO43)
(Bartlett et al. 2013). Whether this difference reflects the mAb themselves,
secondary Ab used or batch of cells remains to be determined. Regardless,
data from the current and past studies combined reveals that P2rx7 mRNA
(by qPCR), total P2X7 receptor protein (by Western blotting) and
cell-surface P2X7 receptor (by confocal microscopy and flow cytometry) is
abundant on EOC13 microglia.
2.4.3 EOC13 cells express functional P2X7 receptor
Consistent with the high amounts of P2X7 receptors on EOC13 cells, the
current study confirmed the presence of robust P2X7 receptor activity on
these cells. Similar to previous studies (Bartlett et al. 2013), 1 mM ATP
induced ethidium+ uptake into EOC13 cells in NaCl medium. Consistent
with P2X7 receptor reactivity, this process was reduced in physiological
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medium which includes 2 mM Ca2+ and 1 mM Mg2+, both of which are
known allosteric inhibitors of P2X7 receptors (Virginio et al. 1997, Yan
et al. 2011). Moreover, the P2X7 receptor antagonist JNJ-47965567
(Bhattacharya et al. 2013) at 10µM reduced ATP-induced ethidium+ uptake
by approximately 66%. This inhibition is comparable to that by the P2X7
receptor antagonist BBG at 30 µM in these cells but less than that of the
P2X7 receptor antagonist AZ10606120 at 10 µM, which completely
impaired 1 mM ATP-induced ethidium+ uptake in EOC13 cells (Bartlett
et al. 2013). This difference between JNJ-47965567 and AZ10606120 is
somewhat surprising given that JNJ-47965567 is reported to be a more
potent inhibitor of murine P2X7 receptor than AZ10606120 (Michel et al.
2009; Bhattacharya et al. 2013). Further studies are required to directly
compare the pharmacological action and potency of these two antagonists in
EOC13 cells. However, it should be noted that both compounds bind to the
same antagonist binding pocket in the P2X7 receptor, with the binding of
JNJ-47965567, but not AZ10606120, significantly altered by amino acid
changes at residues F88 and F108 within this pocket (Karasawa and Kawate
2016). Thus, it would be of interest to sequence this region of the P2rx7 gene
in EOC13 cells, to determine if any missense mutations exist which may
explain the reduced potency of JNJ-47965567 compared to AZ10606120 in
these cells.
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It is also noteworthy that pre-incubation of EOC13 cells with 30% β-CD for
15 min did not affect the ATP-induced ethidium+ uptake compared to
EOC13 cells pre-incubated in the absence of β-CD. Cyclodextrins are
compounds that are widely used as drug vehicles but are also capable of
depleting cholesterol present in the plasma membrane of cells (Al Azzam
and Muhammad 2015). Notably, cholesterol is a negative regulator of the
P2X7 receptor interacting directly with the transmembrane and intracellular
domains of this receptor (Karasawa et al. 2017). Moreover, 15 min
pre-incubation with methyl-β-CD is sufficient to increase P2X7 receptor
activation, while 15 min pre-incubation with α-CD has no effect (Robinson
et al. 2014). The current study indicates that short-term incubation with
β-CD has no significant effect on P2X7 receptor activation similar to that of
α-CD. It remains to be determined if long-term exposure to β-CD alters
P2X7 activation.
The assessment of P2X7 receptor activity in the current study suffered
technical issues. ATP induced a decrease in the size (FSC) of EOC13 cells
in NaCl medium, which resulted in a large proportion of cells moving outside
of the viable cell gate. An effect reduced by pre-incubation with
JNJ-47965567, suggests that this event was mediated, at least in part, by
P2X7 receptor activation. This reduction in cell size was most likely due to
P2X7 receptor-mediated cell death, as P2X7 receptor activation can cause
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the death of EOC13 cells over 24 h (Bartlett et al. 2013). To circumvent this
issue, P2X7 receptor activity in EOC13 cells was assessed in physiological
medium, which due to the presence of Ca2+ and Mg2+ limits P2X7 receptor
activation and thereby would also reduce the decrease in cell size (or cell
death). The decrease in cell size (FSC) was completely prevented in EOC13
cells suspended in physiological medium, which corresponded with
dramatically impaired ATP-induced ethidium+ uptake compared to that in
EOC13 cells suspended in NaCl medium.
2.4.4 EOC13 cells display low amounts of CD39 and ectoATPase activity
The current study revealed for the first time, that EOC13 cells express low
amounts of Entpd1 gene expression and cell-surface CD39, whilst CD39 was
undetectable in EOC13 cell lysates. This low amount of CD39 expression
paralleled the low ectoATPase activity. The failure to detect CD39 by
Western blotting may reflect technical issues as no positive control for CD39
protein was included, although β-actin was detected in EOC13 cells by this
method. EctoATPase activity on EOC13 cells was deemed as low, as
comparable studies in human RT4 bladder epithelial cells resulted in the
liberation of large nmol amounts of phosphate from 100 µM ATP over
30 min (Mansfield and Hughes 2014) compared to low pmol amounts of
phosphate liberated from 100 µM ATP in the current study over 10 to
60 min. Contrary to previous observations (Liao et al. 2010), the current
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study demonstrated the absence of cell-surface CD39 on RAW 264.7 cells.
This result questioned the ability of the anti-CD39 mAb used to detect
murine CD39. However, this mAb was shown to label splenocytes, which
contains populations of CD39 positive leukocytes (Zhou et al. 2009). Thus,
given this observation with splenocytes, and the low CD39 expression by
qPCR and low ectoATPase activity on EOC13 cells, it indicates that the low
cell-surface CD39 expression on EOC13 cells is accurate. The absence of
cell-surface CD39 on RAW 264.7 cells remains unexplained but may reflect
differences between culture conditions between laboratories.
2.4.5 EOC13 microglia as a potential model of ALS microglia
The current study confirms the presence of high P2X7 receptors on EOC13
microglia as previously demonstrated by our laboratory (Bartlett et al. 2013).
The presence of high amounts of the P2X7 receptor on EOC13 microglia
parallels the high amounts of P2X7 receptors on microglia from SOD1 ALS
mice (D’Ambrosi et al. 2009). The negligible amount of CD39 and
ectoATPase activity of EOC13 cells contrasts other studies of primary
murine microglia, which show robust CD39 and ectoATPase activity (Braun
et al. 2000, Bulavina et al. 2013). By comparison, ectoATPase activity is
downregulated on microglia from SOD1 ALS mice (D’Ambrosi et al. 2009).
The expression of Entpd1 mRNA in microglia from the spinal cords of
SOD1G93A mice is also low (Butovsky et al. 2015). Collectively, the high
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P2X7 receptor expression and activity, and the low CD39 expression and
ectoATPase activity on EOC13 cells parallels that of ALS-associated
microglia. It will be of future importance to directly compare P2X7 receptor
and CD39 expression and activity of EOC13 cells and microglia from ALS
mice to determine if EOC13 cells are a model of ALS-associated microglia.
2.4.6 Conclusion
These results demonstrate that murine EOC13 microglia express a relatively
high level of P2X7 but low level of CD39 when compared to murine spleen
cells. This pattern reflects that of ALS-associated microglia indicating that
EOC13 microglia may serve as a potential model to study the ATP-P2X7
signalling axis in microglial events relating to ALS.
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Chapter 3
Efficacy of the P2X7 receptor
antagonist JNJ-47965567 in
amyotrophic lateral sclerosis
progression
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3.1 Background
3.1.1 The SOD1G93A mouse model of ALS
The discovery that the superoxide dismutase-1G93A (SOD1G93A) mutation is
associated with familial amyotrophic lateral sclerosis (fALS) (Rosen et al.
1993) led to the development of the SOD1G93A transgenic mouse model of
ALS, in which mice overexpress multiple copies of human SOD1G93A
(Gurney et al. 1994). Numerous mouse models have since been developed
expressing one of 20 different types of mutations in the SOD1 gene
(Picher-Martel et al. 2016). Nonetheless, the SOD1G93A mouse model
remains the most widely used model for in vivo studies (Lu et al. 2016).
SOD1G93A mice generally display hind limb weakness (the first clinical sign
of ALS) at 3-4 months of age and are completely paralyzed by 5 months of
age (Gurney et al. 1994). However, the onset of ALS varies greatly,
depending on the genetic background and gender of mice (Pfohl et al. 2015).
ALS in SOD1G93A mice resembles many features of ALS in humans,
including axonal and neuromuscular dysfunction, activation of microglia
(microgliosis) and astrocytes (astrogliosis), and motor neuron loss
(McGoldrick et al. 2013). Thus, SOD1G93A mice serve as an important tool
in the investigation of therapeutics in ALS.
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3.1.2 Role of the P2X7 receptor in neuroinflammation in ALS
Neuroinflammation is one of the important factors that contribute to the
progression of ALS (Hooten et al. 2015). The adenosine 5’-triphosphate
(ATP)-P2X7 receptor signalling axis has an emerging role during the
symptomatic stages of ALS. P2X7 receptor can drive microglial activation
and proliferation, potentially leading to a deleterious cycle of
neuroinflammation and neurodegeneration (Monif et al. 2010). The P2X7
receptor is upregulated in the spinal cords of ALS patients (Yiangou et al.
2006) and of SOD1G93A rats (Casanovas et al. 2008). The upregulation of the
P2X7 receptor has also been reported in primary microglia from SOD1G93A
mice (D'Ambrosi et al. 2009). Moreover, the activation of the P2X7 receptor
on microglia expressing SOD1G93A or to a lesser extent wild-type microglia,
causes death of neuronal cells (D’Ambrosi et al. 2009). Similarly, the
activation of P2X7 receptor on SOD1G93A or wild-type astrocytes causes
death of motor neurons (Gandelman et al. 2010).
3.1.3 JNJ-47965567
JNJ-47965567 is a highly specific and potent central nervous system
(CNS)-penetrant P2X7 antagonist which can impair murine P2X7 with a half
maximal inhibitory concentration of 2 nM (Bhattacharya et al. 2013, Letavic
et al. 2013). The brain to plasma ratio of JNJ-47965567 is approximately 1,
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which indicates that this compound can readily penetrate the CNS
(Bhattacharya and Biber 2016). Since JNJ-47965567 has demonstrated
therapeutic efficacy in CNS disorders such as temporal lobe epilepsy
(Jimenez-Pacheco et al. 2016) and neuropathic pain (Bhattacharya et al.
2013), it is an ideal P2X7 receptor antagonist to impair this receptor in other
disease models characterised by neuroinflammation including ALS.
3.1.4 Aims
The current study hypothesised that the highly specific and potent
CNS-penetrant P2X7 receptor antagonist, JNJ-47965567, may demonstrate
therapeutic efficacy in ALS. Thus, this study aimed to determine if
pharmacological blockade of the P2X7 receptor with JNJ-47965567
ameliorates disease progression in SOD1G93A mice.
3.2 Methods
3.2.1 Reagents
Food pellets were from Specialty Feeds (Glen Forrest, WA, Australia).
HydroGel

packs

were

from

ClearH2O

(Westbrook,

ME,

USA).

(2-Hydroxypropyl)-beta-cyclodextrin (β-CD) and paraformaldehyde (PFA)
were from Sigma-Aldrich (St. Louis, MO, USA). JNJ-47965567 was from
Tocris Bioscience (Ellisville, MO, USA). Dulbecco’s phosphate buffered
saline (PBS) was from Thermo Fisher Scientific (Waltham, MA, USA).
63

3.2.2 Animals
All animal experiments were conducted in accordance with the Animal
Ethics Committee of the University of Wollongong (Wollongong, Australia)
(AE16/18).

B6SJL-Tg(SOD1-G93A)1GUr/j

transgenic

ALS

mice

hemizygous for the human SOD1G93A transgene and backcrossed onto
C57BL/6J background were originally provided by Bradley Turner
(University of Melbourne, Melbourne, Australia). Mice were bred and
maintained at the Australian BioResources Animal Facility (Moss Vale,
Australia). Forty-eight SOD1G93A mice aged between 34-75 days were
delivered to the Rodent Facility at the University of Wollongong
(Wollongong, Australia). The relative copy number of the SOD1G93A
transgene was assessed by polymerase chain reaction (PCR) of tail-tip
samples

(provided

by

Australian

BioResources)

as

described

(Bartlett et al. 2017). The relative SOD1G93A transgene copy number was
similar between groups (Dr Diane Ly, personal communication). Mice were
housed in a temperature-controlled environment on a 12:12 h light-dark
cycle in digital ventilated cages (Techniplast, Buguggiate, Italy). Male mice
were housed 1-3 per cage, whereas female mice were housed 2-4 per cage.
Due to fighting, all grouped males were eventually separated and housed
individually before the end of the study period. Food and water were
provided ad libitum. When mice were unable to access food and water easily
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(i.e., clinical score 2) water bottles with long sippers were used, and
moistened food pellets and HydroGel packs were placed on the bottom of
the cages.
3.2.3 Treatments
β-CD was prepared at 0.3 g/mL (30% m/v) in Milli-Q water (vehicle
solution). JNJ-47965567 was solubilised in vehicle solution at 5 mg/mL by
mixing at 45oC for 2 hours and heated sonication for 15 minutes. Both
solutions were filter-sterilised through 0.22 µm filters (Millex GP,
Darmstadt, Germany). Both vehicle and drug were prepared weekly and
stored at 4◦C until required. Cohorts of 24 mice were injected with
JNJ-47965567 (30 mg/kg) or 30% vehicle solution intraperitoneally (i.p.)
three times a week from 101-103 days (d) of age (i.e., disease onset) until
end-stage using Omnican 0.5 mL syringes fitted with 30G needles (Braun,
Melsungen, Germany). Repeat injections were performed on alternating
sides of the abdomen to minimise irritation. Each group consisted of equal
numbers of male and female SOD1G93A mice (12 males and 12 females per
group) matched for age and sex according to ALS Therapy Development
Institute (Scott et al. 2008) and the European ALS/MND Group (Ludolph
et al. 2010) guidelines. One vehicle-treated male mouse died from an
unexpected event unrelated to ALS and was excluded from all analysis.
Throughout the drug trial, researchers were blinded to treatments.
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3.2.4 Animal monitoring
SOD1G93A mice were monitored for body weight, clinical score and motor
coordination (rotarod performance) (Bartlett et al. 2017). All these
parameters were assessed from 41-80 d of age in the morning to minimise
changes due to diurnal variations. Only data from d 80 was included in
analyses, except for rotarod performance, which was from d 95 to obtain at
least two training sessions prior to recording data.
3.2.4.1 Body weight measurement
Body weight loss is a sensitive indicator of disease progression in SOD1G93A
mice (Cervetto et al. 2013, Hatzipetros et al. 2015). Prior to injection, body
weight was assessed three times a week using an OHAUS Explorer precision
balance (Parsippany, NJ, USA). The maximum body weight recorded
between 80-101 d for each mouse was taken as the pre-treatment maximum
body weight of each mouse and used to calculate the percentage body weight
change for each mouse at each subsequent time-point.
3.2.4.2 Clinical scoring
To assess changes in neuromuscular function of SOD1G93A mice, mice were
scored three times a week using criteria based on that of the ALS Therapy
Development Institute (Table 3.1) (Hatzipetros et al. 2015).
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Table 3.1 Clinical scoring system for SOD1G93A mice
Criteria

Score
0
1
2
3
4

When mouse is suspended by the tail, the hindlimb is fully
extended away from the lateral midline
When mouse is suspended by the tail, the hindlimb is collapsed
partially or fully towards lateral midline
When mouse is allowed to walk, toes curl downwards at least
twice during walking OR any part of the foot is dragging along
cage bottom/table
When mouse is allowed to walk there is a forward motion
however the hindlimb is not being used for forward motion
When the mouse is placed on its either side it is not able to right
itself within 10 seconds from either side

3.2.4.3 Rotarod performance
Rotarod performance was used to measure motor coordination of mice once
per week. Prior to disease onset, mice were trained at least twice using a
five-lane accelerating rotarod (RotaRod Advanced, TSE Systems, Hesse,
Germany). For training sessions, the rod was rotated at a constant speed of
10 revolutions per minute (rpm), followed by three runs during which the
rod gradually increased speed from 4-20 rpm over 180 seconds (s), with a
30 s rest interval between runs. For testing, the rod was rotated at a constant
speed of 4 rpm for 5 s, followed by three runs with the rod rotating from
4-20 rpm over 180 s, with a 30 s rest interval between runs. Each mouse on
each test day was given three attempts and the maximum time that each
mouse remained on the rod was recorded as the latency to fall and included
in the data analysis. As disease progressed (i.e., clinical score 2), mice were
unable to stand on the rod for which the latency to fall was recorded as 5 s.
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3.2.5 Survival
Mice were euthanised by slow-fill carbon dioxide inhalation technique when
they reached the ethically approved endpoint of either 20% body weight loss
compared to their initial pre-treatment maximum body weight or when they
were unable to right themselves within 10 s after being placed on either side
(i.e., a score of 4).
Following euthanasia, mice in each treatment cohort were equally divided
into one of two groups for tissue processing, with age-, sex-matched pairs
treated in the same fashion. Whole blood was collected from all mice via
cardiac puncture. Serum was collected by centrifuging blood for 10 minutes
at 14,000 x g and storing the cell-free supernatants at -800C. Mice were then
either perfused with 50 ml PBS, or with 25 ml PBS followed by 25 ml 4%
(m/v) PFA in PBS. Spinal cords and brains from PBS-perfused mice were
stored at -800C. Spinal cords and brains from PFA-perfused were further
fixed with 4% PFA/PBS overnight at 40C followed by incubation in 30%
(m/v) sucrose/PBS for another night (or until tissue has sunk to the bottom)
at 40C and then stored at -800C. All sera, spinal cords and brains were
archived for future analyses, which was beyond the time frame of the current
project.
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3.2.6 Data analysis
All analyses were performed using GraphPad Prism 5.0 (San Diego, CA,
USA). Data are presented as mean ± standard deviation (SD). Differences in
survival between groups were compared by a log-rank (Mantel–Cox) test.
For body weight, the differences between groups were analysed using
unpaired Student’s t-test for the mean body weight percentage for each
mouse over entire period of the study. For clinical score and motor
coordination, differences between groups were compared using a two-way
ANOVA for each mouse at each recorded time-point. Statistical differences
were considered significant when P < 0.05.
3.3 Results
3.3.1 ALS progression was continuous and gender dependent in
SOD1G93A mice
3.3.1.1 ALS progressed continuously from disease onset until end-stage
in SOD1G93A mice
SOD1G93A mice were treated with vehicle solution or JNJ-47965567 from
101-103 d (i.e., disease onset) until end-stage. SOD1G93A mice were
monitored for the progression of ALS by measuring body weight, clinical
score, motor coordination and survival (n = 23, Figure 3.1). Body weight
measurements and clinical score according to the criteria outlined by the
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ALS Therapy Development Institute (Table 3.1) were assessed three times a
week. Motor coordination was measured by rotarod test once a week using
a five-lane accelerating rotarod. Survival of SOD1G93A mice was determined
by one of two criteria; either when SOD1G93A mice lost 20% body weight
compared to their initial pre-treatment maximum body weight, or when mice
were unable to right themselves within 10 s after being placed on either side
(i.e., a score of 4). To explore disease progression in SOD1G93A mice, the
vehicle-treated (control) mice are described first below.
The average clinical score of vehicle-treated SOD1G93A mice at d 80 was 0
with only one mouse with a clinical score of 1. As clinical score increased
gradually, vehicle-treated mice attained average scores of 1 and 2 at d 139
and d 160, respectively. Out of the 23 vehicle-treated mice, only eight mice
were assigned a clinical score greater than 2. The average clinical score
plateaued at a mean score of 2.8 (Figure 3.1 A). On average, vehicle-treated
mice gained weight until d 106 and then declined continuously from d 108
without recovering at any subsequent time points. Body weight declined
gradually from d 108 until d 139, which decreased drastically from d 139
until end-stage (Figure 3.1 B). Similarly, vehicle-treated mice showed
improvements in motor coordination from d 95 to d 123, but this dropped
after d 123 (Figure 3.1 C). The average survival of vehicle-treated mice was
found to be 163 ± 8.8 d. The first mouse reached end-stage at
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d 143 followed by a subsequent decline in survival until d 177
(Figure 3.1 D).
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Figure 3.1 ALS progressed continuously from disease onset until end-stage in
SOD1G93A mice. SOD1G93A mice were injected intraperitoneally with vehicle from
d 101-103 (i.e., disease onset) (↓) three times per week until end-stage of disease. (A)
Clinical score and (B) body weight were measured three times per week from d 80. (C)
Motor coordination was assessed once per week from d 95 by rotarod test and presented
as latency to fall. (D) Survival was determined either by 20% body weight loss compared
to their initial pre-treatment maximum body weight or when mice were unable to right
themselves within 10 s after being placed on either side (i.e., a score of 4). Data is
presented as mean ± SD (n = 23).
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3.3.1.2 ALS progressed more rapidly in male than female SOD1G93A
mice
Gender differences in the progression of ALS in SOD1G93A mice have been
reported previously (Choi et al. 2008, Olivan et al. 2015). Thus, the
parameters above were compared between male and female vehicle-treated
SOD1G93A mice (n = 11,12; Figure 3.2). Average ALS scores over the course
of the study were similar between male and female mice (P = 0.99,
Figure 3.2 A). Likewise, there was no significant difference in motor
coordination between male and female mice (P = 0.47, Figure 3.2 C). In
contrast, weight loss in male mice was greater than in female mice
(Figure 3.2 B). In addition, male mice had significantly lower mean
percentage body weight than female mice when calculated for each mouse
over the entire study period (P = 0.01, Figure 3.2 B Inset). Moreover,
survival was significantly shorter in male (161 ± 4.4 d) compared to female
mice (165 ± 11.3 d) (P = 0.01, Figure 3.2 D).
3.3.2 JNJ-47965567 treatment did not alter ALS progression in
SOD1G93A mice
3.3.2.1 JNJ-47965567 treatment did not alter ALS progression in
SOD1G93A mice
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Figure 3.2 ALS progressed more rapidly in male than female SOD1G93A mice.
SOD1G93A mice were injected intraperitoneally with vehicle from d 101-103 (i.e., disease
onset) (↓), three times per week until end-stage of disease. (A) Clinical score and (B)
body weight were measured three times per week from d 80. Inset shows the mean body
weight over the entire study period. (C) Motor coordination was assessed once per week
from d 95 by rotarod test and presented as latency to fall. (D) Survival was determined
either by 20% body weight loss compared to their initial pre-treatment maximum body
weight or when mice were unable to right themselves within 10 s after being placed on
either side (i.e., a score of 4). Comparisons between male and female mice were done
using (A and C) two-way ANOVA analysis, (B) unpaired Student’s t-tests over the entire
study period or (D) a log-rank (Mantel–Cox) tests. Data is presented as mean ± SD
(n = 11 males and n = 12 females). * P < 0.05.

Next, ALS progression was compared between JNJ-47965567- and
vehicle-treated SOD1G93A mice (n = 23-24, Figure 3.3). Clinical scores were
similar between JNJ-47965567- and vehicle-treated SOD1G93A mice.
JNJ-47965567-treated mice had an average clinical score of 1 at d 132,
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which then increased to an average clinical score of 2 at d 162, after which
the average clinical score slowly increased. This was similar to
vehicle-treated mice (P = 0.724, Figure 3.3 A). Measurements also revealed
similar trends in body weight loss for JNJ-47965567-treated mice compared
to vehicle-treated mice. JNJ-47965567-treated mice began to lose body
weight from d 111 with a rapid decline observed from d 139, which is similar
to the vehicle-treated mice (Figure 3.3 B). In addition, no difference in mean
percentage body weight were observed between JNJ-47965567- and
vehicle-treated mice when calculated over the entire study period
(P = 0.303, Figure 3.3 B Inset). Motor coordination was also similar between
JNJ-47965567-treated and vehicle-treated SOD1G93A mice (P = 0.731).
JNJ-47965567-treated mice followed a similar pattern in decline of motor
coordination from d 139 as described above for vehicle-treated mice
(Figure 3.3 C). Finally, JNJ-47965567 treatment failed to extend the average
survival of mice (165 ± 10.3 d) compared to vehicle treatment (163 ± 8.8 d)
(P = 0.345, Figure 3.3 D). The rate of decline in survival was also similar
between these two treatments (Figure 3.3 D).
3.3.2.2 JNJ-47965567 delayed clinical score progression in female
SOD1G93A mice but was not statistically significant
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Figure 3.3 JNJ-47965567 treatment did not alter ALS progression in SOD1G93A
mice. SOD1G93A mice were injected intraperitoneally either with 30 mg/kg JNJ-47965567
or with vehicle from d 101-103 (i.e., disease onset) (↓), three times per week until disease
end-stage. (A) Clinical score and (B) body weight were measured three times per week
from d 80. Inset shows the mean body weight over the entire study period. (C) Motor
coordination was assessed once per week from d 95 by rotarod test and presented as
latency to fall. (D) Survival was determined either by 20% body weight loss compared to
their initial pre-treatment maximum body weight or when mice were unable to right
themselves within 10 s after being placed on either side (i.e., a score of 4). Comparisons
between vehicle- and JNJ-47965567-treated mice were done using (A and C) two-way
ANOVA analysis (B) unpaired Student’s t-tests over the entire study period (D) a
log-rank (Mantel–Cox) tests. Data is presented as mean ± SD (n = 23 vehicle-treated mice
and n = 24 JNJ-47965567-treated mice).
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Previous studies have reported gender-dependent effects of P2X7 receptor
antagonism in SOD1G93A mice (Cervetto et al. 2013, Bartlett et al. 2017).
Moreover, the data above revealed gender differences in disease progression
in vehicle-treated SOD1G93A mice (Figure 3.2). Therefore, the effect of
JNJ-47965567 treatment was analysed in male and female SOD1G93A mice
separately. Analysis of male mice showed similar clinical score curves for
both vehicle- and JNJ-47965567-treated male mice (P = 0.653,
Figure 3.4 A). In contrast, JNJ-47965567 treatment delayed a rise in the
clinical score in female SOD1G93A mice. JNJ-47965567-treated female mice
stayed longer at average clinical score of 1 from d 132 to d 148 and had lower
clinical score from d 141 until end-stage compared to vehicle-treated female
mice (Figure 3.4 A). However, this difference in clinical score between
treatments in female mice failed to reach statistical significance (P = 0.297).
Body weight loss and motor coordination in JNJ-47965567-treated male or
female mice were not significantly different to corresponding vehicle-treated
male and female mice, respectively (body weight loss: males P = 0.435,
females P = 0.407, Figure 3.4 B and Inset; rotarod performance: males
P = 0.663, females P = 0.378, Figure 3.4 C). Moreover, there was no
difference in survival between treatments in either male or female mice
(males: vehicle 161 ± 4.4 d vs. JNJ-47965567 163 ± 12 d, P = 0.222,
Figure 3.4 D; females: vehicle 165 ± 11.3 d vs. JNJ-47965567 167 ± 8.6 d,
P = 0.882, Figure 3.4 D).
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Figure 3.4 JNJ-47965567 delayed clinical score progression in female SOD1G93A
mice but was not statistically significant. SOD1G93A mice injected intraperitoneally
either with 30 mg/kg JNJ-47965567 or with vehicle from d 101-103 (i.e., disease onset)
(↓), three times per week until end-stage of disease. (A) Clinical score and (B) body
weight were measured three times per week from d 80. Inset shows the mean body weight
over the entire study period. (C) Motor coordination was assessed once per week from
d 95 by rotarod test and presented as latency to fall. (D) Survival was determined either
by 20% body weight loss compared to their initial pre-treatment maximum body weight
or when mice were unable to right themselves within 10 s after being placed on either
side (i.e., a score of 4). Comparisons between vehicle- and JNJ-47965567-treated mice
were done using (A and C) two-way ANOVA analysis (B) unpaired Student’s t-tests over
the entire study period, and (D) a log-rank (Mantel–Cox) tests. Data is presented as
mean ± SD (n = 11-12 males and n = 12 females per treatment).

3.3.2.3 JNJ-47965567 treatment did not alter the frequency of days spent
at a given clinical score in SOD1G93A mice
The above data (Figure 3.4 A) suggests that clinical score may differ between
vehicle- and JNJ-47965567-treated mice. Therefore, to examine the clinical
score data in an alternate fashion, this data was re-examined as the length of
time each mouse received a score of 1, 2 or 3. However, no differences were
observed between treatments in mice when combined or when examined by
gender (Figure 3.5). Both female and male combined mice received a clinical
score of 1 for an average of 22.3 d. Moreover, female and male mice, on
average, received clinical scores of 2 and 3 for 2.7 d and 0.5 d, respectively
(Figure 3.5 A). Similar results were observed in male (Figure 3.5 B) and
female (Figure 3.5 C) mice when examined separately.

78

A

vehicle (n=23)
JNJ-47965567 (n=24)

Frequency of Days at
Clinical Score

40

20

0

-20

1

2

3

Clinical score

B
Males, vehicle (n=11)
Males, JNJ-47965567 (n=12)

20

0

Females, vehicle (n=12)
Females, JNJ-47965567 (n=12)

40

Frequency of Days at
Clinical Score

Frequency of Days at
Clinical Score

40

C
V

20

0

-20

-20

1

2
Clinical score

3

1

2

3

Clinical score

Figure 3.5 JNJ-47965567 treatment did not alter the frequency of days spent at
clinical score 1, 2 and 3 in SOD1G93A mice. SOD1G93A mice were injected
intraperitoneally either with 30 mg/kg JNJ-47965567 or with vehicle from d 101-103 (i.e.,
disease onset), three times per week until end-stage of disease. Clinical score was
measured three times per week from d 80. The frequency of days spent at a clinical score
of 1, 2 or 3 for each mouse from vehicle- and JNJ-47965567-treated group are shown as
(A) all, (B) male, (C) or female vehicle- and JNJ-47965567-treated mice. Symbols
represent individual mice and bars represent group means (n = 11-12 males and n = 12
females per treatment).

3.4 Discussion
The current study showed that the CNS-penetrant P2X7 receptor antagonist
JNJ-47965567 does not alter disease progression in ALS SOD1G93A mice.
This result was the same in either male or female SOD1G93A mice, or when
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combined into treatment groups of both genders. The progression of ALS in
SOD1G93A mice however was found to be continuous from disease onset and
gender dependent, with disease progression more rapid in males than
females.
3.4.1 ALS progression is gender-dependent in SOD1G93A mice
In this study, the progression of ALS in SOD1G93A mice was gender
dependent, with a more rapid disease progression in male than female mice.
This result correlates with findings of previous studies (Choi et al. 2008,
Alves et al. 2011, Cervetto et al. 2013, Olivan et al. 2014). Similar gender
differences also exist in human ALS, with males more prone to ALS than
females (McCombe and Henderson 2010). Delayed disease onset and
prolonged survival in SOD1G93A females is most likely due to the
contribution of the genetic background (Heiman-Patterson et al. 2005, Pfohl
et al. 2015) and/or the protective roles of the sex hormone, estrogen (Choi
et al. 2008). The current study used mice on a B6SJL background. From an
analysis of 97 studies, gender differences in this hybrid strain have been
reported previously, in which female SOD1G93A mice experienced delayed
disease onset and extended lifespans compared to male SOD1G93A mice
(Pfohl et al. 2015). Whilst other studies have shown advanced disease onset
and shortened lifespan in ovariectomized female compared to sham-operated
female SOD1G93A mice (Choi et al. 2008, Yan et al. 2018). Moreover,
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treatment of ovariectomized female SOD1G93A mice with the estrogen,
17b-estradiol, delayed disease progression and extended survival in these
mice (Choi et al. 2008). Combined this supports a role for estrogens in
reducing ALS in female SOD1G93A mice. Thus, these findings reemphasize
the need to consider gender difference in pre-clinical studies of ALS.
3.4.2 JNJ-47965567 treatment did not alter ALS progression in
SOD1G93A mice
In this study, treatment of SOD1G93A mice with JNJ-47965567 (30 mg/kg)
from disease onset failed to slow disease progression and extend survival
compared to vehicle-treated mice. JNJ-47965567, at the same dose
(30 mg/kg), reduced clinical symptoms, and microgliosis and astrogliosis in
a murine model of epilepsy (Jimenez-Pacheco et al. 2016). During the course
of the current study, another CNS-penetrant P2X7 receptor antagonist,
A-804598 (30 mg/kg) from pre-disease onset, d 100, was also shown to have
no effect in slowing disease progression, delaying disease onset or extending
survival in SOD1G93A mice (Fabbrizio et al. 2017). Combined, these two
studies suggest that P2X7 receptor antagonism in the CNS and periphery is
insufficient to ameliorate ALS progression in SOD1G93A mice. These
findings parallel observations in SOD1G93A mice in which constitutive
genetic deletion of P2X7 failed to delay ALS progression (Apolloni et al.
2013a). However, it cannot be excluded that alternate doses and/or regimes

81

with JNJ-47965567 (or A-804598) may reduce disease progression in
SOD1G93A mice. Thus, future studies in SOD1G93A could consider higher
doses, more frequent injections and/or alternate routes of administration of
the compounds.
The above findings with two different CNS-penetrant P2X7 receptor
antagonists contrasts the three previous studies with the non-CNS-penetrant
P2X7 receptor antagonist Brilliant Blue G (BBG) in SOD1G93A mice
(Cervetto et al. 2013, Apolloni et al. 2014, Bartlett et al. 2017). In the first
study, treatment of SOD1G93A mice with BBG (45.5 mg/kg) at disease onset
improved motor coordination in both male and female separately, and
delayed weight loss in male mice and both genders combined (Cervetto
et al. 2013). In the second study, administration of BBG (50 mg/kg)
post-disease onset improved motor coordination, and administration of BBG
(250 mg/kg) from this same time point improved both clinical score and
motor coordination. The effect of BBG was independent of gender (Apolloni
et al. 2014). In the third study, administration of BBG (45.5mg/kg) at late
pre-disease onset delayed weight loss in female mice and both genders
combined, and extended survival in female mice (Bartlett et al. 2017).
Reasons for the observed differences between JNJ-47965567 (this study) or
A-804598 (Fabbrizio et al. 2014) and BBG (Cervetto et al. 2013, Apolloni
et al. 2014, Bartlett et al. 2017) remain unknown. JNJ-47965567 and
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A-804598 are more potent antagonists of the P2X7 receptor compared to
BBG (Bhattacharya and Biber 2016). Thus, given the commencement and
frequency of drug administration, and injection route was similar between
each of the studies in SOD1G93A mice, it appears unlikely that this is a major
cause for the observed differences between JNJ-47965567 (or A-804598)
and BBG. However, differences in tissue distribution and pharmacokinetics
between these compounds are unknown and cannot be excluded. One
possible explanation for the differences observed between JNJ-47965567 (or
A-804598) and BBG may relate to their ability to penetrate the CNS. Both
JNJ-47965567 and A-804598 are CNS-penetrant, whilst BBG is
non-CNS-penetrant (Bhattacharya and Biber 2016). Thus, this data
combined suggests that blockade of systemic P2X7 receptor can ameliorate
ALS progression in SOD1G93A mice (as seen with BBG), but that the effect
is lost when CNS P2X7 is also blocked (as seen with JNJ-47965567 or
A-804598). If true, this indicates systemic P2X7 receptor activation can
promote ALS, whilst CNS P2X7 receptor activation protects against ALS
progression. In support of this concept and as mentioned above, genetic
deletion of the P2X7 receptor in SOD1G93A mice failed to protect against
ALS and in fact worsened disease progression (Apolloni et al. 2013a). An
alternate explanation for the observed differences between JNJ-47965567
(or A-804598) and BBG in SOD1G93A mice is differences in P2X7 receptor
selectivity. Both JNJ-47965567 and A-804598 are highly selective P2X7
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receptor antagonists (Bhattacharya et al. 2013, Donnelly-Roberts et al.
2009). In contrast, BBG is a non-selective P2X7 receptor antagonist, which
can also block other P2X receptors (Jiang et al. 2000), the ATP release
channel pannexin-1 (Qiu and Dahl 2009) and sodium ion channels (Jo and
Bean 2011). Thus, the possibility remains that BBG acts on at least one of
these other molecules in the periphery to ameliorate ALS progression in
SOD1G93A mice.
In the current study, 30% β-CD was used as a vehicle solution. Cyclodextrins
are commonly used as drug vehicles because of their increased aqueous
solubility, stability, bioavailability and reduced irritation (Shimpi et al.
2005). However, cyclodextrins such as methyl-beta-cyclodextrin can deplete
cholesterol in the lipid rafts of plasma membranes (Al Azzam and
Muhammad 2015). Notably, cholesterol is a negative regulator of P2X7
receptor pore formation interacting directly via the transmembrane domains
of the P2X7 receptor (Robinson et al. 2014, Karasawa et al. 2017). Thus, the
possibility remains that administration of β-CD in SOD1G93A mice enhanced
P2X7 receptor activity in these animals and circumvented any inhibitory
benefits associated with JNJ-47965567. However, short-term incubation
with β-CD did not alter ATP-induced ethidium+ uptake into EOC13
microglia compared to EOC13 microglia pre-incubated in the absence of
β-CD (section 2.3.2.2). Nevertheless, future studies could examine if
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long-term β-CD increases P2X7 receptor activation in vitro or in vivo.
JNJ-47965567, prepared in cyclodextrin-base vehicles, has therapeutic
benefits in vivo (Bhattacharya et al. 2013; Jimenez-Pacheco et al. 2016).
Whilst β-CD is a Food and Drug Administration (FDA)- and Therapeutic
Goods Administration (TGA)-approved drug vehicle (Loftssona and
Brewsterb 2010). Thus β-CD was selected for use in vivo. In the current
study, SOD1G93A mice treated with either β-CD or JNJ-47965567 displayed
unexpected side-effects including eye discharge, hair loss and ear necrosis
(results not shown). Given this occurred in both treatment groups, this
indicates that these side-effects were most likely due to β-CD rather than the
antagonist. Furthermore, these side-effects were observed only from
d 150 (results not shown) suggesting that these were a result of chronic
treatment with β-CD. To the best of our knowledge, such side effects have
not been reported for β-CD but the current study suggests the ethical use of
β-CD needs to be further considered in any future long-term studies with this
vehicle.
3.4.3 Limitations
3.4.3.1 End points criteria
In the current study, the ethical end point of SOD1G93A mice was determined
by one of two criteria; either, when SOD1G93A mice lost 20% body weight

85

compared to their initial pre-treatment maximum body weight, or when mice
were unable to right themselves within 10 s after being placed on either side
(i.e., a score of 4). In this study, most mice reached endpoint due to 20%
weight loss with few mice obtaining clinical scores of 2, 3 or 4. This limited
the study of disease progression, especially during the initial stages of the
disease, which may have eliminated the possibility of JNJ-47965567
delaying disease progression towards end-stage. Although the use of these
two end points has been recommended by the ALS Institute (Ludolph et al.
2007, Scott et al. 2008), more appropriate criteria for end points may need
to be argued with ethics committees to study the efficacy of drug treatments
in SOD1G93A mice.
3.4.3.2 Rotarod test
Rotarod tests are the most frequently used test to monitor motor coordination
in ALS mice (Weydt et al. 2003). In the current study, the performance of
SOD1G93A mice in the rotorod test was highly variable. This may reflect
inexperience with this technique. Variability in rotarod performance may
also be due to receiving mice at different ages leading to the younger mice
having more trial runs than older mice before disease onset. In order to
detect deficits in motor coordination more accurately by the rotarod test, all
mice should receive equal number of training sessions or runs before starting
the experiment (Miana-Mena et al. 2005).
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Despite the extensive use of rotarod test in ALS studies, this test is
considered insensitive to detect motor deficits prior to the onset of clinical
symptoms (Knippenberg et al. 2010).

Thus, other tests such as

the Hanging-wire test or foot print analysis could be adopted. These tests are
more reliable and accurate in detecting early motor deficits without the need
for training the mice and are less time consuming than the rotarod test
(Olivan et al. 2014, Knippenberg et al. 2010).
3.4.4 Conclusions
In conclusion, the CNS-penetrant, selective P2X7 receptor antagonist
JNJ-47965567 failed to alter disease progression in SOD1G93A mice. This
data parallels another study using a second CNS-penetrant, the selective
P2X7 receptor antagonist, A-804598 (Fabbrizio et al. 2017). Both studies
contrasted the three studies performed with the non-CNS penetrant,
non-selective P2X7 receptor antagonist BBG (Cervetto et al. 2013, Apolloni
et al. 2014, Bartlett et al. 2017). Combined, these studies suggest that
blockade of systemic, but not the CNS P2X7 receptors, or blockade of
molecules other than the P2X7 receptor, may have therapeutic benefits in
ALS.
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Chapter 4
Conclusions and significance
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4.1 Overview
Amyotrophic lateral sclerosis (ALS) is a complex, progressive and fatal
motor neuron disease. Even after decades of research, the primary factors
that trigger ALS remain unknown. Among the different factors contributing
to

the

progression

of

ALS,

the

involvement

of

the

adenosine 5’-triphosphates (ATP)-P2X7 receptor signalling axis plays a role
in this disease through the activation of microglia and astrocytes to promote
the death of motor neurons (sections 1.3.1 and 1.3.2). The role of the P2X7
receptor in ALS progression has been demonstrated using the P2X7 receptor
antagonist, Brilliant Blue G (BBG), in superoxide dismutase-1G93A
(SOD1G93A) mice (section 1.3.3). Cellular models that closely resembles
ALS-associated models would be beneficial to establish to further
understand the roles of the ATP-P2X7 receptor signalling axis in ALS.
Furthermore, the use of P2X7 receptor antagonists with greater potency,
selectivity and central nervous system (CNS) penetration in vivo may assist
in further establishing the role of the P2X7 receptor in ALS progression.
Thus, this study is set out to (i) investigate EOC13 microglia as a potential
in vitro model of the ATP-P2X7 receptor signalling axis in ALS-associated
microglia (Chapter 2); and (ii) to test the therapeutic potential of P2X7
receptor blockade using the CNS-penetrant, selective P2X7 antagonist,
JNJ-47965567, in reducing ALS progression in SOD1G93A mice (Chapter 3).
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4.2 Conclusions and significance
In Chapter 2, EOC13 microglia were found to express high and low amounts
of P2X7 receptors and CD39, respectively. These amounts correlated with
high and low P2X7 receptor and ectoATPase activity, respectively. These
findings parallel that of ALS-associated microglia. P2X7 receptors are
up-regulated on microglia in human and rodent ALS spinal cords and on
microglia from SOD1G93A mice (Yiangou et al. 2006, Casanovas et al. 2008,
D’Ambrosi et al. 2009), while microglia from SOD1G93A mice express low
ectoATPase activity (D’Ambrosi et al. 2009). Given these similarities,
EOC13 microglia provide a potential model of ALS-associated microglia to
study the role of the ATP-P2X7 receptor signalling axis in ALS in vitro. The
activation of P2X7 receptors present on ALS-associated microglia results in
the release of (unknown) cytotoxic factors which lead to the death of
neuronal cell lines (D’Ambrosi et al. 2009). Thus, it would be of future
importance to determine if P2X7 receptor activation on EOC13 microglia
also results in the release of neurotoxic factors, and then to use EOC13
microglia to identify these unknown factors. In this regard it would also be
of importance to further characterise the phenotype of EOC13 cells given the
dual role of microglia in ALS (toxic versus protective phenotype) (Liao
et al. 2012, Geloso et al. 2017). The availability of an in vitro model of
ALS-associated microglia may facilitate the study of molecular mechanisms
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associated in ALS, which in turn may facilitate the identification of potential
therapeutic targets to prevent ALS progression in vivo.
In Chapter 3, the administration of JNJ-47965567 into SOD1G93A mice from
clinical disease onset failed to alter disease progression. This result
paralleled a second study using the CNS-penetrant, selective P2X7
antagonist A-804598 in SOD1G93A mice (Fabbrizio et al. 2017). This study
was published during the course of the JNJ-47965567 trial, but similarly
showed no effect on ALS progression. These two studies contrast other work
with the non-CNS penetrant, non-selective P2X7 antagonist BBG, which
showed efficacy in reducing ALS progression in SOD1G93A mice (Cervetto
et al. 2013, Apolloni et al. 2014, Bartlett et al. 2017). Findings from these
five studies suggest that the blockade of systemic (peripheral) P2X7 receptor
can ameliorate ALS progression in SOD1G93A mice, but that this effect is lost
when the CNS P2X7 receptor is also blocked. It will be of future value to
directly compare the effect of JNJ-47965567 and BBG in SOD1G93A mice
simultaneously to validate a role for the systemic P2X7 receptors in ALS
disease progression. If this concept is true it may suggest that P2X7 receptor
activation in the CNS may be beneficial in slowing ALS. Thus, the study of
this receptor in EOC13 microglia may reveal protective rather than cytotoxic
roles in relation to neuronal cells.
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An alternative reason for the observed difference between JNJ-47965567 (or
A-804598) and BBG in SOD1G93A mice may be differences in P2X7 receptor
selectivity. Both JNJ-47965567 (IC50 = 10 nM) and A-804598 (IC50 = 2 nM)
are highly selective P2X7 receptor antagonists (Bhattacharya and Biber
2016). In contrast, BBG is a non-selective P2X7 receptor antagonist capable
of inhibiting other P2X receptors (Jiang et al. 2000), as well as the
ATP-release channel pannexin-1 (Qiu and Dahl 2009) and sodium channels
(Jo and Bean 2011). Thus, the possibility remains that BBG acts on channels
other than P2X7 receptors to ameliorate ALS progression in SOD1G93A mice.
Thus, it will also be of future value to compare the effect of BBG with other
specific but non-CNS-penetrant P2X7 receptor antagonists, such as
A740003 (Honore et al. 2006) in SOD1G93A mice to determine if systemic
P2X7 receptor or other channels play a role in ALS progression.
Greater understanding of the potential role of systemic and CNS P2X7
receptors in ALS progression in SOD1G93A mice may in turn reveal
therapeutic targets to ameliorate this disease in humans.

92

References
Abe, K, Itovama, Y, Sobue, G, Tsuji, S, Aoki, M, Doyu, M, Hamada, C,
Kondo, K, Yoneoka, T, Akimoto, M & Yoshino, H 2014, 'Confirmatory
double-blind, parallel-group, placebo-controlled study of efficacy and
safety of edaravone (MCI-186) in amyotrophic lateral sclerosis
patients',

Amyotrophic

Lateral

Sclerosis

and

Frontotemporal

Degeneration, vol. 15, pp. 610–617.
Adinolfi, E, Giuliani, AL, Marchi, ED, Pegoraro, A, Orioli, E & Di Virgilio,
F 2018, ‘The P2X7 receptor: A main player in inflammation’,
Biochemical Pharmacology, vol. 151, pp. 234–244.
Al Azzam, KM & Muhammad, E 2015, ‘Host-guest inclusion complexes
between Mitiglinide and the naturally occurring Cyclodextrins alpha,
beta, and gamma: a theoretical approach’, Advanced Pharmaceutical
Bulletin, vol. 5, pp. 289–291.
Al-Chalabi, A & Hardiman, O 2013, 'The epidemiology of ALS: a
conspiracy of genes, environment and time', Nature Reviews, vol. 9, pp.
617–628.
Al-Chalabi, A, van den Berg, LH & Veldink, J 2017, ‘Gene discovery in
amyotrophic lateral sclerosis: implications for clinical management’,
Nature Reviews Neurology, vol. 13, pp. 96–104.
Alves, CJ, de Santana, LP, Santos, AJ, de Oliveira, GP, Duobles, T, Scorisa,
JM, Martins, RS, Maximino, JR & Chadi, G 2011, ‘Early motor and
electrophysiological

changes

in

transgenic

mouse

model

of

amyotrophic lateral sclerosis and gender differences on clinical
outcome’, Brain Research, vol. 1394, pp. 90–104.

93

Apolloni, S, Amadio, S, Montilli, C, Volonte, C & D’Ambrosi, N 2013a,
'Ablation of P2X7 receptor exacerbates gliosis and motoneuron death
in the SOD1-G93A mouse model of amyotrophic lateral sclerosis’,
Human Molecular Genetics, vol. 22, no. 20, pp. 4102–4116.
Apolloni, S, Amadio, S, Parisi, C, Matteucci, A, Potenza, RL, Armida, M,
Popoli, P, D'Ambrosi, ND & Volonte, C 2014, 'Spinal cord pathology
is ameliorated by P2X7 antagonism in a SOD1-mutant mouse model of
amyotrophic lateral sclerosis', Disease Models & Mechanisms, vol. 7,
pp. 1101–1109.
Apolloni, S, Parisi, C, Pesaresi, MG, Rossi, S, Carri, MT, Cozzolino, M,
Volonte, C & D’Ambrosi, N 2013b, ‘The NADPH Oxidase Pathway is
dysregulated by the P2X7 receptor in the SOD1-G93A Microglia
Model of amyotrophic lateral sclerosis’, The Journal of Immunology,
vol. 190, pp. 5187–5195.
Barbeito, LH, Pehar, M, Cassina, P, Vargas, MR, Peluffo, H, Viera, L,
Estevez, AG & Beckman, JS 2004, 'A role for astrocytes in motor
neuron loss in amyotrophic lateral sclerosis', Brain Research. Brain
Research Reviews, vol. 47, pp. 263–274.
Bartlett, R, Sluyter, V, Watson, D, Sluyter, R & Yerbury, JJ 2017, 'P2X7
antagonism using Brilliant Blue G reduces body weight loss and
prolongs survival in female SOD1G93A amyotrophic lateral sclerosis
mice', PeerJ, vol. 5, pp. 1–29.
Bartlett, R, Yerbury, JJ & Sluyter R 2013, 'P2X7 receptor activation induces
reactive oxygen species formation and cell death in murine EOC13
microglia', Mediators of Inflammation, vol. 2013, pp. 1–18.

94

Becher, B, Spath, S & Goverman, J 2017, ‘Cytokine networks in
neuroinflammation’, Nature Reviews Immunology, vol. 17, pp. 49–59.
Beers, DR, Henkel, JS, Xiao, Q, Zhao, W, Wang, J, Yen, AA, Siklos, L,
McKecher, SR & Appel, SH 2006, ‘Wild-type microglia extend
survival in PU.1 knockout mice with familial amyotrophic lateral
sclerosis’, PNAS, vol. 103, pp. 16021–16026.
Bensimon, G, Lacomblez, L & Meininger, V 1994, ‘A controlled trial of
riluzole in amyotrophic lateral sclerosis’, The New England Journal of
Medicine, vol. 330, pp. 585–591.
Bhattacharya, A & Biber, K 2016, ‘The microglial ATP-gated ion channel
P2X7 as a CNS drug target’, Glia, vol. 64, no. 10, pp. 1772–1787.
Bhattacharya, A, Wang, Q, Ao, H, Shoblock, JR, Lord, B, Aluisio, L, Fraser,
I, Nepomuceno, D, Neff, RA, Welty, N, Lovenberg, TW, Bonaventure,
P, Wickenden, AD & Letavic, MA 2013, ‘Pharmacological
characterization of a novel centrally permeable P2X7 receptor
antagonist: JNJ-47965567’, British Journal of Pharmacology, vol. 170,
pp. 624–640.
Block, ML 2008, 'NADPH oxidase as a therapeutic target in Alzheimer’s
disease', BMC Neuroscience, vol. 9, no. 2, pp. 1–8.
Boillee, S, Vande Velde, C & Cleveland DW 2006, 'ALS: a disease of motor
neurons and their nonneuronal neighbors', Neuron, vol. 52, pp. 39–59.
Braun, N, SeÂvigny, J, Robson, SC, Enjyoji, K, Guckelberger, O, Hammer,
K, Di Virgilio, F & Zimmermann, H 2000, ‘Assignment of
ecto-nucleoside triphosphate diphosphohydrolase-1/cd39 expression to
microglia and vasculature of the brain’, European Journal of
95

Neuroscience, Vol. 12, pp. 4357–4366.
Bruijn, LI, Houseweart, MK, Kato, S, Anderson, KL, Anderson, SD, Ohama,
E, Reaume, AG, Scott, RW & Cleveland, DW 1998, ‘Aggregation and
motor neuron toxicity of an ALS-linked SOD1 mutant independent
from wild-type SOD1’, Science, vol. 281, pp. 1851–1854.
Brundin, P, Melki, R & Kopito, R 2010, ‘Prion-like transmission of protein
aggregates in neurodegenerative diseases’, Nature Reviews Molecular
Cell Biology, vol. 11, pp. 301–307.
Bulavina, L, Szulzewsky, F, Rocha, A, Krabbe, G, Robson, SC, Matyash, V
& Kettenmann, H 2013, ‘NTPDase 1 activity attenuates microglial
phagocytosis’, Purinergic Signalling, vol. 9, pp. 199–205.
Burnstock, G 2016, ‘An introduction to the roles of purinergic signaling in
neurodegeneration,

neuroprotection

and

neuroregeneration’,

Neuropharmacology, vol. 104, pp. 4-17.
Butovsky, O, Jedrychowski, MP, Cialic, R, Krasemann, S, Murugaiyan, G,
Fanek, Z, Greco, DJ, Wu, PM, Doykan, CE, Kiner, O, Lawson, RJ,
Frosch, MP, Pochet, N, Fatimy, RE, Krichevsky, AM, Gygi, SP,
Lassmann, H, Berry, J, Cudkowicz, ME & Weiner, HL 2015,
‘Targeting miR-155 restores abnormal microglia and attenuates disease
in SOD1 mice’, Annals of Neurology, vol.77, pp. 75-99.
Casanovas, A, Hernandez, S, Tarabal, O, Rossello, J & Esquerda, JE 2008,
‘Strong P2X4 purinergic receptor-like immunoreactivity is selectively
associated with degenerating neurons in transgenic rodent models of
amyotrophic lateral sclerosis’, Journal of Comparative Neurology,
vol. 506, pp. 75–92.

96

Cervetto, C, Frattaroli, D, Maura, G & Marcoli, M 2013, 'Motor neuron
dysfunction in a mouse model of ALS: Gender dependent effect of
P2X7 antagonism', Toxicology, vol. 311, pp. 69-77.
Cherry, JD, Olschowka, JA & O’Banion, MK 2014, ‘Neuroinflammation
and M2 microglia: the good, the bad, and the inflamed’, Journal of
Neuroinflammation, vol. 11, pp. 1–15.
Choi, CI, Lee, YD, Gwag, BJ, Cho, SI, Kim, SS & Suh-Kim, H 2008,
‘Effects of estrogen on lifespan and motor functions in female hSOD1
G93A transgenic mice’, Journal of Neurological Sciences, vol. 268, no.
1–2, pp. 40–47.
Clement, AM, Nguyen, MD, Roberts, EA, Garcia, ML, Boillee, S, Rule, M,
Mc-Mahon, AP, Doucette, W, Siwek, D, Ferrante, RJ, Brown Jr, RH,
Julien, JP, Goldstein, LS & Cleveland DW 2003, ‘Wild-type
nonneuronal cells extend survival of SOD1 mutant motor neurons in
ALS mice’, Science, vol. 302, pp. 113–117.
Coddou C, Yan Z, Obsil T, Huidobro-Toro JP & Stojilkovic SS 2011,
'Activation and regulation of purinergic P2X receptor channels',
Pharmacological Reviews, vol. 63, pp. 641–683.
Cozzolino, M, Pesaresi, MG, Gerbino, V, Grosskreutz, J & Carri, MT 2012,
'Amyotrophic lateral sclerosis: new insights into underlying molecular
mechanisms

and

opportunities

for

therapeutic

intervention',

Antioxidants and Redox Signalling, vol. 17, pp. 1277-1330.
D'Ambrosi, N, Finocchi, P, Apolloni, S, Cozzolino, M, Ferri, A, Padovano,
V, Pietrini, G, Carrì, MT & Volonte, C 2009, ‘The proinflammatory
action of microglial P2 receptors is enhanced in SOD1 models for

97

amyotrophic lateral sclerosis’, The Journal of Immunology, vol. 183,
pp. 4648-4656.
Di Virgilio, F, Borea, PA & Illes, P 2001, ‘P2 receptors meet the immune
system’, Trends in Pharmacological Sciences, vol. 22, pp. 5–7.
Di Virgilio, F, Bronte, V, Collavo, D & Zanovello, P 1989, ‘Responses of
mouse lymphocytes to extracellular adenosine 5’-triphosphate (ATP).
Lymphocytes with cytotoxic activity are resistant to the permeabilizing
effects of ATP’, Journal of Immunology, vol. 143, pp. 1955–1960.
Di Virgilio, F, Dal Ben, D, Sarti, AC, Giuliani, AL & Falzoni, S 2017, ‘The
P2X7 receptor in infection and inflammation’, Immunity, vol. 47,
pp. 15–31.
Di Virgilio, F, Schmalzing, G & Markwardt, F 2018, ‘The elusive P2X7
macropore’, Trends in Cell Biology’, vol. 28, no. 5, pp. 392–404.
Donnelly-Roberts DL, Namovic, MT, Surber, B, Vaidyanathan, SX,
Perez-Medrano, A, Wang, Y, Carroll, WA & Jarvis, MF 2009,
‘[3H]A-804598

([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-

ylguanidine) is a novel, potent, and selective antagonist radioligand for
P2X7 receptors’, Neuropharmacology, vol. 56, pp. 223–229.
Du, L, Zhang, Y, Chen, Y, Zhu, J, Yang, Y & Zhang, HL 2016, ‘Role of
microglia in neurological disorders and their potentials as a therapeutic
target’, Molecular Neurobiology, vol. 54, no. 10, pp. 7567–7584.
Fabbrizio, P, Amadio, S, Apolloni, S & Volonte, C 2017, ‘P2X7 receptor
activation modulates autophagy in SOD1-G93A mouse microglia’,
Frontiers of Cellular Neuroscience, vol. 11, no. 249, pp. 1–12.

98

Ferrari, D, Chiozzi, P, Falzoni, S, Dal Susino, M, Collo, G, Buell, G, Di
Virgilio, F 1997, ‘ATP-mediated cytotoxicity in microglial cells’,
Neuropharmacology, vol. 36, no. 9, pp. 1295–1301.
Franco, MC, Ye, Y, Refakis, CA, Feldman, JL, Stokes AL, Basso, M, Melero
Fernández de Mera RM, Sparrow, NA, Calingasan, NY, Kiaei, M,
Rhoads, TW, Ma, TC, Grumet, M, Barnes, S, Beal, MF, Beckman, JS,
Mehl, R & Estévez, AG 2013, ‘Nitration of Hsp90 induces cell death’,
PNAS, vol. 110, pp. 1102-1111.
Gandelman, M, Levy, M, Cassina, P, Barbeito, L & Beckman, JS 2013,
'P2X7 ATP receptor-induced death of motor neurons by a
peroxynitrite/FAS-dependent pathway', Journal of Neurochemistry,
vol. 126, pp. 382–388.
Gandelman, M, Peluffo, H, Beckman, JS, Cassina, P & Barbeito, L 2010,
'Extracellular ATP and the P2X7 receptor in astrocytemediated motor
neuron death: implications for amyotrophic lateral sclerosis', Journal of
Neuroinflammation, vol. 7, pp. 33–42.
Geloso, MC, Corvino, V, Marchese, E, Serrano, A, Michetti, F &
D’Ambrosi, N 2017, ‘The dual role of microglia in ALS: Mechanisms
and therapeutic approaches’, Frontiers in Aging Neuroscience, vol. 9,
no. 242, pp. 1–10.
Geraghty, NJ, Mansfield, KJ, Fuller, SJ, Watson, D & Sluyter, R 2017, ‘The
P2X7 receptor is not essential for development of imiquimod-induced
psoriasis-like inflammation in mice’, Purinergic Signalling, vol. 13,
no. 4, pp. 405–415.
Gonnord, P, Delarasse, C, Auger, R, Benihoud, K, Prigent, M Cuif, MH,

99

Lamaze, C & Kanellopoulos, JM 2009, ‘Palmitoylation of the P2X7
receptor, an ATP-gated channel, controls its expression and association
with lipid rafts’, The FASEB Journal, vol. 23, pp. 795–805.
Gravel, M, Béland, LC, Soucy, G, Abdelhamid, E, Rahimian, R, Gravel, C
& Kriz, J 2016, ‘IL-10 controls early microglial phenotypes and disease
onset in ALS caused by misfolded superoxide dismutase 1’, Journal of
Neuroscience, vol. 36, pp. 1031–1048.
Greenbaum, D, Colangelo, C, Williams, K & Gerstein, M 2003, ‘Comparing
protein abundance and mRNA expression levels on a genomic scale’,
Genome Biology, vol. 4, no. 9, p. 117.
Gu, BJ, Duce, JA, Valova, VA, Wong, B, Bush, AI, Petrou, S & Wiley, JS
2012, ‘P2X7 receptor-mediated scavenger activity of mononuclear
phagocytes toward non-opsonized particles and apoptotic cells is
inhibited by serum glycoproteins but remains active in cerebrospinal
fluid’, The Journal of Biological Chemistry, vol. 287, no. 21, pp.
17318–17330.
Gu, BJ, Saunders, BM, Jursik, C & Wiley, JS 2010, ‘The P2X7-nonmuscle
myosin membrane complex regulates phagocytosis of nonopsonized
particles and bacteria by a pathway attenuated by extracellular ATP’,
Blood, vol. 115, no. 8, pp. 1621–1631.
Gu, BJ, Saunders, BM, Petrou, S & Wiley, JS 2011, ‘P2X7 is a scavenger
receptor for apoptotic cells in the absence of its ligand, extracellular
ATP’, The Journal of Immunology, vol. 187, pp. 2365–2375.
Gurney, ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD,
Caliendo, J, Hentati, A, Kwon, YW, Deng, HX, Chen, W, Zhai, P, Sufit,

100

RL & Siddique, T 1994, 'Motor neuron degeneration in mice that
express a human Cu, Zn superoxide dismutase mutation', Science,
vol. 264, pp. 1772–1775.
Harikrishnareddy, D, Misra, S, Upadhyay, S, Modi, M & Medhi, B 2015,
'Roots to start research in amyotrophic lateral sclerosis: molecular
pathways and novel therapeutics for future', Reviews in the
Neurosciences, vol. 26, pp. 161–181.
Hattori, M & Gouaux, E 2012, ‘Molecular mechanism of ATP binding and
ion channel activation in P2X receptors’, Nature, vol. 485,
pp. 207–212.
Hatzipetros, T, Kidd, JD, Moreno, AJ, Thompson, K, Gill, A & Vieira, FG
2015, ‘A quick phenotypic neurological scoring system for evaluating
disease progression in the SOD1-G93A mouse model of ALS’, Journal
of Visualized Experiments, vol. 104, pp. 1–6.
He, Y, Taylor, N, Fourgeaud, L & Bhattacharya, A 2017, ‘The role of
microglial P2X7: modulation of cell death and cytokine release’,
Journal of Neuroinflammation, vol. 14, pp. 1–13.
Heiman-Patterson, TD, Deitch, JS, Blankenhorn, EP, Erwin, KL, Perreault,
MJ, Alexander, BK, Byers, N, Toman, I & Alexander, GM 2005,
‘Background

and

gender

effects

on

survival

in

the

TgN

(SOD1-G93A)1 Gur mouse model of ALS’, Journal of the
Neurological Sciences, vol. 236, pp. 1–7.
Honore, P, Donnelly-Roberts, D, Namovic, MT, Hsieh, G, Zhu, CZ, Mikusa,
JP, Hernandez, G, Zhong, C, Gauvin, DM, Chandran, P, Harris, R,
Medrano, AP, Carroll, W, Marsh, K, Sullivan, JP, Faltynek, CR &

101

Jarvis,

MK

2006,

quinolinylamino)

‘A-740003

[N-(1-{[(cyanoimino)(5-

methyl]amino}-2,2-dimethylpropyl)-2-(3,4-

dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor
antagonist, dose-dependently reduces neuropathic pain in the rat’,
Journal of Pharmacology Experimental Therapeutics, vol. 319,
pp. 1376–1385.
Hooten, KG, Beers, DR, Zhao,W & Appel, SH 2015, ‘Protective and toxic
neuroinflammation

in

amyotrophic

lateral

sclerosis’,

Neurotherapeutics, vol. 12, no. 2, pp. 364–375.
Illes, P, Khan, TM & Rubini, P 2017, ‘Neuronal P2X7 receptors revisited:
do they really exist?’, Journal of Neuroscience, vol. 37, no. 30,
pp. 7049–7062.
Jaarsma D, Teuling E, Haasdijk ED, De Zeeuw CI & Hoogenraad CC 2008,
‘Neuron-specific expression of mutant superoxide dismutase is
sufficient to induce amyotrophic lateral sclerosis in transgenic mice’,
Journal of Neuroscience, vol. 28, pp. 2075–2088.
Jarvis, MF & Khakh, BS 2009, 'ATP-gated P2X cation-channels',
Neuropharmacology, vol. 56, no. 1, pp. 208–215.
Jiang, LH, Baldwin, JM, Roger, S & Baldwin, SA 2013, 'Insights into the
molecular mechanisms underlying mammalian P2X7 receptor
functions and contributions in diseases, revealed by structural modeling
and single nucleotide polymorphisms', Frontiers of Pharmacology, vol.
4, no. 55, pp. 1–14.
Jiang, LH, Mackenzie, AB, North, RA & Surprenant, A 2000, ‘Brilliant Blue
G selectively blocks ATP-gated rat P2X7 receptors’, Molecular

102

Pharmacology, vol. 58, pp. 82–88.
Jimenez-Pacheco, A, Olivos-Ore, LA, Artalejo, AR, Alves, M, Letavic, M,
Miras-Portugal, MT, Conroy, RM, Delanty, N, Farrell, MA, O’Brien,
DF, Bhattacharya, A, Engel, T & Henshall, DC 2016, ‘Transient P2X7
receptor antagonism produces lasting reductions in spontaneous
seizures and gliosis in experimental temporal lobe epilepsy’, The
Journal of Neuroscience, vol. 36, no. 22, pp. 5929–5932.
Jo S & Bean BP 2011, ‘Inhibition of neuronal voltage-gated sodium channels
by Brilliant Blue G’, Molecular Pharmacology, vol. 80, pp. 247–257.
Karasawa, A & Kawate, T 2016, ‘Structural basis for subtype-specific
inhibition of the P2X7 receptor’, ELife, vol. 5, pp. 1–17.
Karasawa, A, Michalski, K, Mikhelzon, P & Kawate, T 2017, ‘The P2X7
receptor forms a dye-permeable pore independent of its intracellular
domain but dependent on membrane lipid composition’, Elife, vol. 6,
pp. 1–22.
Kaur, SJ, McKeown, SR & Rashid, S 2016, 'Mutant SOD1 mediated
pathogenesis of Amyotrophic Lateral Sclerosis', ScienceDirect,
vol. 577, pp. 109–118.
Kawate, T, Michel, JC, Birdsong, WT & Gouaux, E 2009, ‘Crystal structure
of the ATP-gated P2X4 ion channel in the closed state’, Nature,
vol. 460, no. 7255, pp. 592–598.
Kiernan, MC, Vucic, S, Cheah, BC, Turner, MR, Eisen, A, Hardiman, O,
Burrell, JR & Zoing, MC 2011, 'Amyotrophic lateral sclerosis', Lancet,
vol. 377, pp. 342–355.

103

Knippenberg, S, Thau, N, Dengler, R, & Petri, S 2010, ‘Significance of
behavioural tests in a transgenic mouse model of amyotrophic lateral
sclerosis (ALS)’, Behavioural Brain Research, vol. 213, pp. 82–87.
Kurashima, Y, Amiya, T, Nochi, T, Fujisawal, K, Haraguchi, T, Iba, H,
Tsutsui, H, Sato, S, Nakajima, S, Iijima, H, Kubo, M, Kunisawa, J &
Kiyono, H 2012, ‘Extracellular ATP mediates mast cell-dependent
intestinal

inflammation

through

P2X7

purinoceptors’, Nature

Communications, vol. 2, no. 1034, pp. 1–12.
Lenertz, LY, Wang, Z, Guadarrama, A, Hill, LM, Gavala, ML & Bertics, PJ
2010, ‘Mutation of putative N-linked glycosylation sites on the human
nucleotide receptor P2X7 reveals a key residue important for receptor
function’, Biochemistry, vol. 49, pp. 4611–4619.
Letavic, MA, Lord, B, Bischoff, F, Hawryluk, NA, Pieters, S, Rech, JC,
Sales, Z, Velter, AI, Ao, H, Bonaventure, P, Contreras, V, Jiang, X,
Morton, KL, Scott, B, Wang, Q, Wickenden, AD, Carruthers, NI &
Bhatacharya, A 2013, ‘Synthesis and Pharmacological Characterization
of Two Novel, Brain Penetrating P2X7 Antagonists’, ACS Medicinal
Chemistry Letters, vol. 4, pp. 419–422.
Lévesque, SA, Kukulski, F, Enjyoji, K, Robson, SC & Sévigny, J 2010,
‘NTPDase1

governs

P2X7-dependent

functions

in

murine

macrophages’, European Journal of Immunology, vol. 40, no. 5,
pp. 1473–1485.
Liao, B, Zhao, W, Beers, DR, Henkel, JS & Appel, SH 2012,
‘Transformation from a neuroprotective to a neurotoxic microglial

104

phenotype in a mouse model of ALS’, Experimental Neurology,
vol. 237, pp. 147–152.
Liao, H, Hyman, MC, Baek, AE, Fukase, K & Pinsky, DJ 2010,
‘cAMP/CREB-mediated transcriptional regulation of ectonucleoside
triphosphate diphosphohydrolase 1 (CD39) expression’, The Journal of
Biological Chemistry, vol. 285, no. 19, pp. 14791–14805.
Liddelow, SA, Guttenplan, KA, Clarke, LE, Bennett, FC, Bohlen, CJ,
Schirmer, L, Bennett, ML, Münch, AE, Chung, WS, Peterson, TC,
Wilton, DK, Frouin, A, Napier, BA, Panicker, N, Kumar, M,
Buckwalter, MS, Rowitch, DH, Dawson, VL, Dawson, TM, Stevens, B
& Barres, BA 2017, ‘Neurotoxic reactive astrocytes are induced by
activated microglia’, Nature, vol. 541, no. 7638, pp. 481487.
Lino, MM, Schneider, C & Caroni, P 2002, ‘Accumulation of SOD1 mutants
in postnatal motoneurons does not cause motoneuron pathology or
motoneuron disease’, Journal of Neuroscience, vol. 22, pp. 4825–4832.
Liu, L, Zou, J, Liu, X, Jiang, LH & Li, J 2010, ‘Inhibition of ATP-induced
macrophage death by emodin via antagonizing P2X7 receptor’,
European Journal of Pharmacology, vol. 640, no. 1-3, pp. 15–19.
Loftssona, T & Brewsterb, ME 2010, ‘Pharmaceutical applications of
cyclodextrins: basic science and product development’, Journal of
Pharmacy and Pharmacology, vol. 62, pp. 1607–1621.
Lu, H, Le, WD, Xie, Y & Wang, X 2016, 'Current therapy of drugs in
amyotrophic lateral sclerosis', Current Neuropharmacology, vol. 14,
pp. 314–321.
Ludolph, AC, Bendotti, C, Blaugrund, E, Chio, A, Greensmith, L, Loeffler,
105

J, Mead, R, Niessen, HG, Petri, S, Pradat, P, Robberecht, W, Ruegg, M,
Schwalenstöcker, B Detlev, S, van den Berg, L, Vieira, F & von
Horsten S 2010, ‘Guidelines for preclinical animal research in
ALS/MND: A consensus meeting’, Amyotrophic Lateral Sclerosis,
vol. 11, vol. 1–2, pp. 38–45.
Mansfield, KJ & Hughes, JR 2014, ‘P2Y receptor modulation of ATP release
in the urothelium’, BioMed Research International, vol. 2014, pp. 1–8.
Mansoor, SE, Lü, W, Oosterheert, W, Shekhar, M, Tajkhorshid, E & Gouaux
E 2016, ‘X-ray structures define human P2X3 receptor gating cycle and
antagonist action’, Nature, vol. 538, pp. 66 –71.
Marín-García, P, Sánchez-Nogueiro, J, Gómez-Villafuertes, R, León, D &
Miras-Portugal, MT 2008, ‘Synaptic terminals from mice midbrain
exhibit

functional

P2X7

receptor’,

Neuroscience,

vol.

151,

pp. 361–373.
Mathis, S, Couratier, P, Julian A, Corcia, P & Le Masson G 2017, ‘Current
view and perspectives in amyotrophic lateral sclerosis’, Neural
Regeneration Research, vol. 12, no. 2, pp.181–184.
McCombe, PA & Henderson, RD 2010, ‘Effects of gender in amyotrophic
lateral sclerosis’, Gender Medicine, vol. 7, no. 6, pp. 557–570.
McGoldrick, P, Joyce, PI, Fisher, EMC & Greensmith, L 2013, ‘Rodent
models of amyotrophic lateral sclerosis’, Biochimica et Biophysica
Acta, vol. 1832, pp. 1421–1436.
Miana-Mena, FJ, Muñoz, MJ, Yagüe, G, Mendez, M, Moreno, M, Ciriza, J,
Zaragoza, P & Osta R 2005, ‘Optimal methods to characterize the

106

G93A mouse model of ALS’, Amyotrophic Lateral Sclerosis and Other
Motor Neuron Disorders, vol. 6, pp. 55–62.
Michel, AD, Ng, SW, Roman, S, Clay, WC, Dean, DK & Walter, DS 2009,
‘Mechanism

of

action

antagonists’,

British

of

Journal

species-selective
of

P2X(7)

Pharmacology,

receptor

Vol.

156,

pp. 1312–1325.
Monif, M, Burnstock, G & Williams, DA 2010, 'Microglia: Proliferation and
activation driven by the P2X7 receptor', The International Journal of
Biochemistry & Cell Biology, vol. 42, pp. 1753–1756.
Monif, M, Reid, CA, Powell, KL, Smart, ML & Williams, DA 2009, ‘The
P2X7 receptor drives microglial activation and proliferation: A trophic
role for P2X7R pore’, The Journal of Neuroscience, vol. 29, no. 12,
pp. 3781–3791.
Nagai, M, Re, DB, Nagata, T, Chalazonitis, A, Jessell, TM, Wichterle, H &
Przedborskim S 2007, 'Astrocytes expressing ALS-linked mutated
SOD1 release factors selectively toxic to motor neurons', Nature
Neuroscience, vol. 10, pp. 615–622.
Nimmerjahn, A, Kirchhoff, F & Helmchen, F 2005, 'Neuroscience: resting
microglial cells are highly dynamic surveillants of brain parenchyma in
vivo', Science, vol. 308, no. 5726, pp. 1314–1318.
Ohgomori, T, Yamada, J, Takeuchi, H, Kadomatsu, K & Jinno, S 2016,
‘Comparative morphometric analysis of microglia in the spinal cord of
SOD1G93A transgenic mouse model of amyotrophic lateral sclerosis’,
European Journal of Neuroscience, vol. 43, pp. 1340–1351.

107

Olivan, S, Calvo, AC, Rando, A, Munoz, MJ, Zaragoza, P & Osta, R 2015,
‘Comparative study of behavioural tests in the SOD1 G93A mouse
model of amyotrophic lateral sclerosis’, Experimental Animals, vol. 64,
no. 2, pp. 147–153.
Oliveira-Giacomelli, Á, Naaldijk, Y, Sardá-Arroyo, L, Goncalves, MCB,
Corrêa-Velloso, J, Pillat, MM, de Souza, HDN & Ulrich, H 2018,
‘Purinergic receptors in neurological diseases with motor symptoms:
targets for therapy’, Frontiers in Pharmacology, vol. 9, no. 325,
pp. 1–28.
Ou, A, Gu, BJ & Wiley, JS 2018, ‘The scavenger activity of the human P2X7
receptor differs from P2X7 pore function by insensitivity to antagonists,
genetic variation and sodium concentration: Relevance to inflammatory
brain diseases’, Biochimica et Biophysica Acta, vol. 1864, no. 4,
pp. 1051–1059.
Paez-Colasante, X, Figueroa-Romero, C, Sakowski, SA, Goutman, SA &
Feldman, EL 2015, 'Amyotrophic lateral sclerosis: mechanisms and
therapeutics in the epigenomic era', Nature Reviews Neurology, vol. 11,
pp. 266–279.
Parisi, C, Napoli, G, Pelegrin, P & Volonte, C 2016, ‘M1 and M2 functional
imprinting of primary microglia: Role of P2X7 activation and
miR-125b’, Mediators of Inflammation, vol. 2016, pp. 1–9.
Perez-Flores, G, Hernandez-Silva, C, Gutierrez-Escobedo, G, De Las Penas,
A, Castano, I, Arreola, J & Perez-Cornejo, P 2016, ‘P2X7 from j774
murine macrophages acts as a scavenger receptor for bacteria but not
yeast’, Biochemical and Biophysical Research Communications, vol.
481, pp. 19–24.
108

Petry, F, Botto, M, Holtappels, R, Walport, MJ & Loos, M 2001,
‘Reconstitution of the Complement Function in C1q-Deficient (C1qa−/−)
Mice with Wild-Type Bone Marrow Cells’, The Journal of Immunology,
vol. 167, no. 7, pp. 4033–4037.
Pfohl, SR, Halicek, MT & Mitchell, CS 2015, ‘Characterization of the
contribution of genetic background and gender to disease progression
in the SOD1 G93A mouse model of amyotrophic lateral sclerosis: A
meta-analysis’, Journal of Neuromuscular Disease, vol. 2, no. 2,
pp. 137–150.
Philips, T & Robberecht, W 2011, 'Neuroinflammation in amyotrophic
lateral sclerosis: role of glial activation in motor neuron disease', The
Lancet Neurology, vol. 10, pp. 253–263.
Picher-Martel, V, Valdmanis, PN, Gould, PV, Julien, J & Dupre, N 2016,
'From animal models to human disease: a genetic approch for
personalized

medicine

in

ALS',

Acta

Neuropathologica

Communications, vol. 4, no. 70, pp. 1–29.
Pramatarova, A, Laganiere, J, Roussel, J, Brisebois, K & Rouleau, GA 2001,
‘Neuron-specific expression of mutant superoxide dismutase 1 in
transgenic mice does not lead to motor impairment’, Journal of
Neuroscience, vol. 21, pp. 3369–3374.
Qiu, F & Dahl, G 2009, ‘A permeant regulating its permeation pore:
inhibition of pannexin 1 channels by ATP’, American Journal of
Physiology Cell Physiology, vol. 296, pp. C250–C255.
Ransohoff, RM 2016, ‘A polarizing question: do M1 and M2 microglia
exist?’, Nature Neuroscience, vol. 19, no. 8, pp. 987–991.

109

Rao, S, Tortola, L, Perlot, T, Wirnsberger, G, Novatchkova, M, Nitsch,R,
Sykacek, P, Frank, L, Schramek, D, Komnenovic, V, Sigl, V, Aumayr,
K, Schmauss, G, Fellner, N, Handschuh, S, Glösmann, M, Pasierbek,
P, Schlederer, M, Resch, GP, Ma, Y, Yang, H, Popper, H, Kenner, L,
Kroemer, G & Penninger, JM 2014, ‘A dual role for autophagy in a
murine model of lung cancer’, Nature Communications, vol. 5,
pp. 1–15.
Reaume, AG, Elliott, JL, Hoffman, EK, Kowall, NW, Ferrante, RJ, Siwek,
DF, Wilcox, HM, Flood, DG, Beal, MF, Brown Jr, RH, Scott, RW &
Snider

WD

1996,

‘Motor

neurons

in

Cu/Zn

superoxide

dismutase-deficient mice develop normally but exhibit enhanced cell
death after axonal injury’, Nature Genetics, vol. 13, pp. 43–47.
Robberecht, W & Philips, T 2013, ‘The changing scene of amyotrophic
lateral sclerosis’, Nature Reviews Neuroscience, vol. 14, pp. 248–264.
Robinson, LE, Shridar, M, Smith, P & Murrell-Lagnado, RD 2014,
‘Regulator of human and rodent P2X7 receptor activation and
sensitization’, The Journal of Biology Chemistry, vol. 289, no. 46,
pp. 31983–31994.
Rosen, DR, Siddique, T, Patterson, D, Figlewicz, DA, Sapp, P, Hentati, A,
Donaldson, D, Goto, J, O'Regan, JP, Deng, HX, Rahmani, Z, Krizus,
A, mckenna-Yasek, D, Cayabyab, A, Gaston, SM, Berger, R, Tanzi,
RE, Halperin, JJ, Herzfeldt, B, Bergh, RVD, Hung, WY, Bird, T, Deng,
G, Mulder, D, Smyth, C, Laing, NG, Soriano, E, Pericak-Vance, MA,
Haines, J, Rouleau, GA, Gusella, JS, Horvitz, HR & Brown, RH
1993, 'Mutations in Cu/Zn superoxide dismutase gene are associated
with familial amyotrophic lateral sclerosis', Nature, vol. 364,
pp. 59–62.
110

Rowland, LP 2001, ‘How amyotrophic lateral sclerosis got its name: the
clinical-pathologic genius of Jean-Martin Charcot’, Archives of
Neurology, vol. 58, no. 3, pp. 512–515.
Salaro, E, Rambaldi, A, Falzoni, S, Amoroso, FS, Franceschini, A, Sarti,
AC, Bonora, M, Cavazzini, F, Rigolin, GM, Ciccone, M, Audrito, V,
Deaglio, S, Pelegrin, P, Pinton, P, Cuneo, A & Di Virgilio, F 2016,
‘Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation
and death’, Scientific Reports, vol. 6, pp. 1–13.
Sánchez-Nogueiro, J, Marín-García, P & Miras-Portugal, MT 2005,
‘Characterization of a functional P2X7-like receptor in cerebellar
granule neurons from P2X7 knockout mice’, FEBS Letter, vol. 579, pp.
3783–3788.
Savio, LEB, de Andrade Mello, P, da Silva, CG & Coutinho-Silva, R 2018,
‘The P2X7 Receptor in Inflammatory Diseases: Angel or Demon?’,
Frontiers in Pharmacology, vol. 9, no. 52, pp. 1–31.
Schulze-Lohoff, E, Hugo, C, Rost, S, Arnold, S, Gruber, A, Brune, B &
Sterzel, RB 1998 ‘Extracellular ATP causes apoptosis and necrosis of
cultured mesangial cells via P2Z/P2X7 receptors’, American Journal of
Physiology-Renal Physiology, vol. 275, pp. 962–971.
Scott, S, Kranz, JE, Cole, J, Lincecum, JM, Thompson, K, Kelly, N,
Bostrom, A, Theodoss, J, Al0Nakhala, BM, Vieira, FG, Ramasubbu, J
& Heywood, JA 2008, ‘Design, power, and interpretation of studies in
the standard murine model of ALS’, Amyotrophic Lateral Sclerosis,
vol. 9, pp. 4–15.

111

Sebastian-Serrano, A, de Diego-Garcia, L, Martinez-Frailes, C, Avila, J,
Zimmermann, H, Millan, JL, Miras-Portugal, MT & Diaz-Hernandez,
M 2014, ‘Tissue-nonspecific alkaline phosphatase regulates purinergic
transmission in the central nervous system during development and
disease’, Computational and Structural Biotechnology Journal, vol. 13,
pp. 95–100.
Shimpi, S, Chauhan, B & Shimpi, P 2005, ‘Cyclodextrins: Application in
different routes of drug administration’, Acta Pharmaceutica, vol. 55,
pp. 139–156.
Silverman, JM, Fernando, S, Grad, LI, Hill, AF, Turner, BJ & Yerbury JJ
2016, ‘Cashman NR. Disease mechanism in ALS: misfolded SOD1
transferred through exosome-dependent and -independent pathways’,
Cellular and Molecular Neurobiology, vol. 36, pp. 377–381.
Sim, JA, Young, MT, Sung, HY, North, RA & Surprenant, A 2004,
‘Reanalysis of P2X7 receptor expression in rodent brain’, Journal of
Neuroscience, vol. 24, pp. 6307–6314.
Skaper, SD, Facci, L, Culbert, AA, Evans, NA, Chessell, I, Davis, JB &
Richardson, JC 2006, ‘P2X7 receptors on microglial cells mediate
injury to cortical neurons in vitro’, Glia, vol. 54, pp. 234–242.
Sluyter, R & Vine, KL 2016, ‘N-Alkyl-substituted Isatins enhance P2X7
receptor-induced interleukin-1β release from murine macrophages’,
Mediators of Inflammation, vol. 2016, pp. 1–10.
Sluyter, R 2017a, ‘The P2X7 receptor’, Advances in Experimental Medicine
and Biology, vol. 1051, pp. 17–53.

112

Sluyter, R, Bartlett, R, Ly, D & Yerbury, JJ 2017b, ‘P2X7 receptor
antagonism in amyotrophic lateral sclerosis’, Neural Regeneration
Research, vol. 12, no. 5, pp. 749–750.
Smart, ML, Gu, B, Panchal, RG, Wiley,J, Cromer, B, Williams, DA &
Petrou, S 2003, ‘P2X7 receptor cell surface expression and cytolytic
pore formation are regulated by a distal C-terminal region’, Journal of
Biological Chemistry, vol. 278, pp. 8853–8860.
Soo, KY, Halloran, M, Sundaramoorthy, V, Parakh, S, Toth, RP, Southam,
KA, McLean, CA, Lock, P, King, A, Farg, MA & Atkin, JD 2015, 'Rab
1-dependent ER-Golgi transport dysfunction is a common pathogenic
mechanism in SOD1, TDP-43 and FUS-associated ALS', Acta
Neuropathologica, vol. 130, no. 5, pp. 679–697.
Sperlágh, B, Vizi, ES, Wirkner, K & Illes, P 2006, ‘P2X7 receptors in the
nervous system’, Progress in Neurobiology, vol. 78, pp. 327–346.
Sun, C, Heid, ME, Keyel, PA & Salter, RD 2013, ‘The Second
Transmembrane Domain of P2X7 Contributes to Dilated Pore
Formation’, PLoS ONE, vol.8, no. 4, pp. 1–10.
Surprenant, A, Rassendren, F, Kawashima, E, North, RA & Buell, G 1996,
‘The cytolytic P2Z receptor for extracellular ATP identified as a P2X
receptor (P2X7)’, Science, vol. 272, pp. 735–738.
Tang, Y & Le, W 2016, ‘Differential roles of M1 and M2 microglia in
neurodegenerative diseases’, Molecular Neurobiology, vol. 53, pp.
1181–1194.
Taylor, SR, Gonzalez-Begne, M, Dewhurst, S, Chimini, G, Higgins, CF,
Melvin, JE & Elliott, JI 2008, ‘Sequential shrinkage and swelling
113

underlie P2X7-stimulated lymphocyte phosphatidylserine exposure and
death’, Journal of Immunology, vol. 180, pp. 300–308.
Turner, BJ & Talbot, K 2008, 'Transgenics, toxicity and therapeutics in
rodent models of mutant SOD1-mediated familial ALS', Progress in
Neurobiology, vol. 85, pp. 94–134.
Virginio, C, Church, D, North RA & Surprenant, A 1997, ‘Effects of divalent
cations, protons and calmidazolium at the rat P2X7 receptor’,
Neuropharmacology, vol. 36, pp. 1285–1294.
Volonte, C, Apolloni, S, Carri, MT & D’Ambrosi, N 2011, ‘ALS: Focus on
purinergic signalling’, Pharmacology & Therapeutics, vol. 132,
pp. 111–122.
Volonte, C, Apolloni, S, Parisi, C & Amadio, S 2016, ' Purinergic
contribution to amyotrophic lateral sclerosis', Neuropharmacology, vol.
104, pp. 180–193.
Volonte, C, Apolloni, S, Skaper, SD & Burnstock, G 2012, 'P2X7 receptors:
channels, pores and more', CNS & Neurological Disorders-Drug
Targets, vol. 11, pp. 705–721.
Weisman, GA, Camden, JM, Peterson, TS, Ajit, D, Woods, LT & Erb, L
2012, 'P2 receptors for extracellular nucleotides in the central nervous
system:

role

of

P2X7

and

P2Y2

receptor

interactions

in

neuroinflammation', Molecular Neurobiology, vol. 46, pp. 96–113.
Weydt, P, Hong, SY, Kliot, M, & Möller, T 2003, ‘Assessing disease onset
and progression in the SOD1 mouse model of AlS’, Neuroreport, vol.
14, pp. 1051–1054.

114

Wijesekera, LC & Leigh, PN 2009, 'Amyotrophic lateral sclerosis', Orphanet
Journal of Rare Diseases, vol. 4, pp. 1–22.
Wilson, HL, Wilson, SA, Surprenant, A & North, RA 2002, ‘Epithelial
membrane proteins induce membrane blebbing and interact with the
P2X7 receptor C terminus’, The Journal of Biological Chemistry,
vol. 277, pp. 34017–34023.
Yamamoto, M, Kamatsuka, Y, Ohishi, A, Nishida, K & Nagasawa, K 2013,
‘P2X7 receptors regulate engulfing activity of non-stimulated resting
astrocytes’, Biochemical and Biophysical Research Communications,
vol. 439, pp. 90–95.
Yamanaka, K, Boillee, S, Roberts, EA, Garcia, ML, McAlonis-Downes, M,
Mikse, OR, Cleveland, DW & Goldstein, LS 2008, ‘Mutant SOD1 in
cell types other than motor neurons and oligodendrocytes accelerates
onset of disease in ALS mice’, PNAS, vol. 105, pp. 7594–7599
Yan, L, Liu, Y, Sun, C, Zheng, Q, Hao, P, Zhai, J & Liu, Y 2018, ‘Effects of
Ovariectomy in an hSOD1-G93A Transgenic Mouse Model of
Amyotrophic Lateral Sclerosis (ALS)’, Medical Science Monitor,
vol. 24, pp. 678–686.
Yan, Z, Khadra, A, Li, S, Tomic, M, Sherman, A & Stojilkovic, SS 2010,
‘Experimental characterization and mathematical modeling of P2X7
receptor channel gating’, Journal of Neuroscience, vol. 30,
pp. 14213–14224.
Yan, Z, Khadra, A, Sherman, A & Stojilkovic, SS 2011, ‘Calcium-dependent
block of P2X7 receptor channel function is allosteric’, The Journal of
General Physiology, vol. 138, no. 4, pp. 437–452.

115

Yegutkin GG 2014, ‘Enzymes involved in metabolism of extracellular
nucleotides and nucleosides: Functional implications and measurement
of activities’, Critical Reviews in Biochemistry and Molecular Biology,
vol. 49, no. 6, pp. 473–497.
Yegutkin, GG 2008, 'Nucleotide- and nucleoside-converting ectoenzymes:
Important modulators of purinergic signalling cascade', Biochimica et
Biophysica Acta, vol. 1783, pp. 673–694.
Yiangou, Y, Facer, P, Durrenberger, P, Chessell, IP, Naylor, A, Bountra, C,
Banati,

RR

&

Anand,

P

2006,

‘COX-2,

CB2

and

P2X7-immunoreactivities are increased in activated microglial
cells/macrophages of multiple sclerosis and amyotrophic lateral
sclerosis spinal cord’, BMC Neurology, vol.6, pp. 1–14.
Zeineddine, R & Yerbury, JJ 2015, ‘The role of micropinocytosis in the
propagation of protein aggregation associated with neurodegenerative
diseases’, Frontiers in Physiology, vol. 6, no.277, pp. 1–8.
Zhao, W, Beers, DR, Henkel, JS, Zhang, W, Urushitani, M, Julien, JP &
Appel,

SH

2010,

‘Extracellular

mutant

SOD1

induces

microglial-mediated motoneuron injury’, GLIA, vol. 58, pp. 231–243.
Zhao, W, Xie, W, Xiao, Q, Beers, DR & Appel, SH 2006. ‘Protective effects
of an anti-inflammatory cytokine, interleukin-4, on motoneuron
toxicity induced by activated microglia’, Journal of Neurochemistry,
vol. 99, pp. 1176–1187.
Zhou, Q, Yan, J, Putheti, P, Wu, Y, Sun, X, Toxavidis, V, Tigges, J, Kassam,
N, Enjyoji, K, Robson, SC, Strom, TB & Gao, W 2009, ‘Isolated CD39
expression on CD4+ T cells denotes both regulatory and memory

116

populations’,

American

Journal

of

Transplantation,

vol.

9,

pp. 2303–2311.

117

APPENDIX A: Supplementary methods
LADMAC conditioned medium
LADMAC cells were cultured in DMEM/F12 medium supplemented with
10% FBS and 2 mM GlutaMAX at 37oC and 95% air/ 5% CO2 for 5-6 days.
Cells and cultured medium were centrifuged (5 min at 300 x g). The
cell-free supernatant was then filtered through 0.22 µm filters (Millex GP,
Darmstadt, Germany) and stored at -20o C until required.
Solutions
Phosphate-buffered saline (PBS), pH 7.4
137 mM Potassium chloride

0.2 g/L

2.7 mM Potassium dihydrogen Phosphate

0.2 g/L

10 mM Sodium chloride

8 g/L

1.8 mM Disodium hydrogen phosphate

1.14 g/L

ACK lysis buffer, pH 7.4
155 mM NH4Cl

8.29 g/L

10 mM KHCO3

1 g/L

0.1 mM Na2EDTA

0.038 g/L

4 X SDS-PAGE loading buffer
0.5 M Tris-HCl (pH 6.8)

130 ml/L

40 % Glycerol (w/v)
8% SDS (w/v)
0.02% Bromophenol blue (w/v)
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SDS-PAGE running buffer (10x)
1.92 M Glycine

143 g/L

35 mM Sodium dodecyl sulphate

10 g/L

0.25 M Tris(hydroxymethyl)- methylamine

30 g/L

Western transfer buffer
150 mM NaCL

14.61 g/L

20% Methanol (v/v)
25 mM Tris (hydroxymethyl)methyl amine

3.02 g/L

1 x Tris-buffered saline containing Tween-20
192 mM Glycine

14.4 g/L

10 mM Tris base

1.18 g/L

10 mM Tris HCl

6.35 g/L

0.05% Tween-20
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APPENDIX B: Supplementary data
Appendix B1: Protein concentrations in EOC13 cell lysates were
determined with a BCA protein assay using increasing concentrations of
bovine serum albumin as a standard (as indicated). Results are representative
of two independent experiments.
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Appendix B2: Standard curves for estimating phosphate and protein
concentrations in the molybdite assay using increasing concentrations of
KH2PO4 and bovine serum albumin as a standard (as indicated). Results are
representative of two independent experiments.
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